Epstein-Barr	B-protein
virus	I-protein
nuclear	I-protein
antigen	I-protein
2	I-protein
and	O
latent	B-protein
membrane	I-protein
protein	I-protein
independently	O
transactivate	O
p53	B-protein
through	O
induction	O
of	O
NF-kappaB	B-protein
activity	O
.	O

B-cell	B-cell_type
immortalization	O
by	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
is	O
dependent	O
on	O
permanent	O
control	O
of	O
the	O
cellular	O
processes	O
which	O
normally	O
regulate	O
cell	O
division	O
and	O
apoptosis	O
,	O
functions	O
possessed	O
by	O
p53	B-protein
in	O
a	O
number	O
of	O
normal	O
cell	O
types	O
.	O

In	O
studies	O
initiated	O
to	O
evaluate	O
relationships	O
between	O
EBV	B-DNA
latent	I-DNA
genes	I-DNA
and	O
p53	B-protein
,	O
p53	B-protein
levels	O
were	O
found	O
to	O
increase	O
approximately	O
10-fold	O
4	O
to	O
5	O
days	O
after	O
EBV	O
infection	O
of	O
purified	O
resting	B-cell_type
human	I-cell_type
B	I-cell_type
cells	I-cell_type
;	O
the	O
induced	O
p53	B-protein
was	O
transcriptionally	O
active	O
.	O

Latent	B-protein
membrane	I-protein
protein	I-protein
1	I-protein
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
EBV	B-protein
nuclear	I-protein
antigen	I-protein
2	I-protein
mediated	O
the	O
increase	O
in	O
p53	B-protein
levels	O
via	O
activation	O
of	O
the	O
NF-kappaB	B-protein
transcription	B-protein
factor	I-protein
.	O

JournaL	NULL
or	NULL
VirRoLOoGY	NULL
,	NULL
July	NULL
1996	NULL
,	NULL
p.	NULL
4849-4853	NULL
0022-538	NULL
Copyright	NULL
©	NULL
1996	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

70	NULL
,	NULL
No	NULL
.	NULL

7	NULL
Epstein-Barr	NULL
Virus	NULL
Nuclear	NULL
Antigen	NULL
2	NULL
and	NULL
Latent	NULL
Membrane	NULL
Protein	NULL
Independently	NULL
Transactivate	NULL
p53	NULL
through	NULL
Induction	NULL
of	NULL
NF-	NULL
«	NULL
kB	NULL
Activity	NULL
WEIPING	NULL
CHEN	NULL
anp	NULL
NEIL	NULL
R.	NULL
COOPER*	NULL
Department	NULL
of	NULL
Immunology	NULL
,	NULL
Scripps	NULL
Research	NULL
Institute	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
California	NULL
Received	NULL
22	NULL
December	NULL
1995/Accepted	NULL
3	NULL
April	NULL
1996	NULL
B-cell	NULL
immortalization	NULL
by	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
is	NULL
dependent	NULL
on	NULL
permanent	NULL
control	NULL
of	NULL
the	NULL
cellular	NULL
processes	NULL
which	NULL
normally	NULL
regulate	NULL
cell	NULL
division	NULL
and	NULL
apoptosis	NULL
,	NULL
functions	NULL
possessed	NULL
by	NULL
p53	NULL
in	NULL
a	NULL
number	NULL
of	NULL
normal	NULL
cell	NULL
types	NULL
.	NULL

In	NULL
studies	NULL
initiated	NULL
to	NULL
evaluate	NULL
relationships	NULL
between	NULL
EBV	NULL
latent	NULL
genes	NULL
and	NULL
p53	NULL
,	NULL
p53	NULL
levels	NULL
were	NULL
found	NULL
to	NULL
increase	NULL
approximately	NULL
10-fold	NULL
4	NULL
to	NULL
5	NULL
days	NULL
after	NULL
EBV	NULL
infection	NULL
of	NULL
purified	NULL
resting	NULL
human	NULL
B	NULL
cells	NULL
;	NULL
the	NULL
induced	NULL
p53	NULL
was	NULL
transcriptionally	NULL
active	NULL
.	NULL

Latent	NULL
membrane	NULL
protein	NULL
1	NULL
and	NULL
,	NULL
to	NULL
a	NULL
lesser	NULL
extent	NULL
,	NULL
EBV	NULL
nuclear	NULL
antigen	NULL
2	NULL
mediated	NULL
the	NULL
increase	NULL
in	NULL
p53	NULL
levels	NULL
via	NULL
activation	NULL
of	NULL
the	NULL
NF-B	NULL
transcription	NULL
factor	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
,	NULL
a	NULL
ubiquitous	NULL
human	NULL
herpesvirus	NULL
,	NULL
is	NULL
closely	NULL
associated	NULL
with	NULL
a	NULL
number	NULL
of	NULL
lymphoid	NULL
and	NULL
epithelial	NULL
malignancies	NULL
,	NULL
including	NULL
endemic	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
,	NULL
a	NULL
number	NULL
of	NULL
T-cell	NULL
lymphomas	NULL
,	NULL
several	NULL
subtypes	NULL
of	NULL
Hodgkin	NULL
's	NULL
dis-ease	NULL
,	NULL
undifferentiated	NULL
nasopharyngeal	NULL
carcinoma	NULL
,	NULL
and	NULL
certain	NULL
other	NULL
carcinomas	NULL
(	NULL
11	NULL
,	NULL
27	NULL
,	NULL
40	NULL
,	NULL
51	NULL
)	NULL
.	NULL

Particularly	NULL
striking	NULL
is	NULL
the	NULL
frequent	NULL
presence	NULL
of	NULL
the	NULL
EBV	NULL
genome	NULL
in	NULL
the	NULL
lymphomas	NULL
that	NULL
occur	NULL
in	NULL
immunocompromised	NULL
individuals	NULL
,	NULL
including	NULL
AIDS	NULL
patients	NULL
and	NULL
transplant	NULL
recipients	NULL
(	NULL
6	NULL
,	NULL
21	NULL
,	NULL
25	NULL
,	NULL
56	NULL
)	NULL
.	NULL

More	NULL
than	NULL
half	NULL
of	NULL
all	NULL
human	NULL
malignancies	NULL
,	NULL
regardless	NULL
of	NULL
the	NULL
cell	NULL
of	NULL
origin	NULL
,	NULL
exhibit	NULL
mutations	NULL
in	NULL
the	NULL
p53	NULL
tumor	NULL
suppressor	NULL
gene	NULL
.	NULL

Among	NULL
EBV-associated	NULL
tumors	NULL
,	NULL
p53	NULL
mutations	NULL
are	NULL
frequent	NULL
in	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
(	NULL
12	NULL
,	NULL
14	NULL
,	NULL
61	NULL
)	NULL
,	NULL
moderately	NULL
common	NULL
in	NULL
AIDS-associated	NULL
lymphomas	NULL
(	NULL
5	NULL
,	NULL
36	NULL
,	NULL
45	NULL
)	NULL
and	NULL
Hodgkin	NULL
's	NULL
disease	NULL
Reed	NULL
Sternberg	NULL
cells	NULL
(	NULL
57	NULL
)	NULL
,	NULL
and	NULL
infrequent	NULL
in	NULL
nasopharyngeal	NULL
carcinoma	NULL
(	NULL
9	NULL
,	NULL
52	NULL
)	NULL
and	NULL
posttransplant	NULL
lymphomas	NULL
(	NULL
8	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
functions	NULL
of	NULL
p53	NULL
and	NULL
the	NULL
mechanisms	NULL
of	NULL
its	NULL
actions	NULL
are	NULL
not	NULL
fully	NULL
understood	NULL
,	NULL
numerous	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
wild-type	NULL
(	NULL
wt	NULL
)	NULL
p53	NULL
regulates	NULL
cell	NULL
cycle	NULL
progression	NULL
,	NULL
prevents	NULL
unrestricted	NULL
cell	NULL
division	NULL
,	NULL
and	NULL
induces	NULL
apoptosis	NULL
in	NULL
some	NULL
cell	NULL
types	NULL
with	NULL
damaged	NULL
DNA	NULL
(	NULL
29	NULL
,	NULL
39	NULL
)	NULL
.	NULL

Such	NULL
functions	NULL
would	NULL
prevent	NULL
unregulated	NULL
or	NULL
abnormal	NULL
cell	NULL
growth	NULL
and	NULL
retard	NULL
the	NULL
development	NULL
of	NULL
tumors	NULL
.	NULL

EBV	NULL
infection	NULL
of	NULL
normal	NULL
B	NULL
lymphocytes	NULL
in	NULL
vitro	NULL
generates	NULL
latently	NULL
infected	NULL
immortal	NULL
B-lymphoblastoid	NULL
cell	NULL
lines	NULL
(	NULL
LCL	NULL
)	NULL
;	NULL
this	NULL
process	NULL
requires	NULL
the	NULL
virus	NULL
to	NULL
permanently	NULL
control	NULL
the	NULL
cellular	NULL
processes	NULL
which	NULL
regulate	NULL
cell	NULL
division	NULL
and	NULL
apoptosis	NULL
,	NULL
functions	NULL
which	NULL
are	NULL
p53	NULL
dependent	NULL
in	NULL
a	NULL
number	NULL
of	NULL
normal	NULL
cell	NULL
types	NULL
.	NULL

The	NULL
present	NULL
studies	NULL
were	NULL
initiated	NULL
to	NULL
evaluate	NULL
the	NULL
relationships	NULL
between	NULL
EBV	NULL
genes	NULL
and	NULL
p53	NULL
during	NULL
the	NULL
earliest	NULL
stages	NULL
of	NULL
EBV	NULL
infection	NULL
and	NULL
transformation	NULL
of	NULL
human	NULL
B	NULL
cells	NULL
.	NULL

EBV	NULL
infection	NULL
of	NULL
resting	NULL
B	NULL
cells	NULL
increases	NULL
cellular	NULL
levels	NULL
of	NULL
transcriptionally	NULL
active	NULL
p53	NULL
.	NULL

We	NULL
found	NULL
low	NULL
levels	NULL
of	NULL
p53	NULL
in	NULL
dense	NULL
resting	NULL
(	NULL
nonactivated	NULL
)	NULL
human	NULL
B	NULL
cells	NULL
purified	NULL
from	NULL
tonsils	NULL
(	NULL
32	NULL
)	NULL
and	NULL
higher	NULL
levels	NULL
in	NULL
both	NULL
short-	NULL
and	NULL
long-term	NULL
LCL	NULL
established	NULL
by	NULL
in	NULL
vitro	NULL
infection	NULL
with	NULL
EBV	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
findings	NULL
which	NULL
are	NULL
consistent	NULL
with	NULL
other	NULL
reports	NULL
(	NULL
4	NULL
,	NULL
53	NULL
)	NULL
.	NULL

Exons	NULL
5	NULL
to	NULL
8	NULL
of	NULL
four	NULL
such	NULL
LCL	NULL
were	NULL
amplified	NULL
by	NULL
PCR	NULL
and	NULL
directly	NULL
sequenced	NULL
(	NULL
AmpliTag	NULL
cycle	NULL
sequencing	NULL
kit	NULL
;	NULL
Perkin-Elmer	NULL
Ce-	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
Department	NULL
of	NULL
Immunology	NULL
,	NULL
IMM-19	NULL
,	NULL
Scripps	NULL
Research	NULL
Institute	NULL
,	NULL
10666	NULL
N.	NULL
Torrey	NULL
Pines	NULL
Rd	NULL
.	NULL

,	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
92037	NULL
.	NULL

Phone	NULL
:	NULL
(	NULL
619	NULL
)	NULL
554-8152	NULL
.	NULL

Fax	NULL
:	NULL
(	NULL
619	NULL
)	NULL
554-6881	NULL
.	NULL

Electronic	NULL
mail	NULL
address	NULL
:	NULL
nrcooper	NULL
@	NULL
scripps.edu	NULL
.	NULL

4849	NULL
tus	NULL
)	NULL
,	NULL
using	NULL
primers	NULL
lying	NULL
just	NULL
outside	NULL
the	NULL
exon	NULL
boundaries	NULL
,	NULL
and	NULL
were	NULL
found	NULL
to	NULL
be	NULL
wt	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
a	NULL
result	NULL
that	NULL
was	NULL
anticipated	NULL
from	NULL
earlier	NULL
studies	NULL
(	NULL
12	NULL
)	NULL
.	NULL

These	NULL
data	NULL
suggested	NULL
that	NULL
EBV	NULL
infection	NULL
increases	NULL
p53	NULL
levels	NULL
.	NULL

In	NULL
order	NULL
to	NULL
evaluate	NULL
this	NULL
possibility	NULL
and	NULL
determine	NULL
the	NULL
time	NULL
course	NULL
of	NULL
p53	NULL
induction	NULL
,	NULL
we	NULL
incubated	NULL
purified	NULL
EBV	NULL
strain	NULL
B95-8	NULL
(	NULL
37	NULL
)	NULL
with	NULL
purified	NULL
resting	NULL
human	NULL
tonsil	NULL
B	NULL
cells	NULL
and	NULL
periodically	NULL
took	NULL
samples	NULL
for	NULL
assessment	NULL
of	NULL
p53	NULL
expression	NULL
by	NULL
the	NULL
Western	NULL
blotting	NULL
technique	NULL
.	NULL

For	NULL
the	NULL
latter	NULL
,	NULL
DO-1	NULL
monoclonal	NULL
antibody	NULL
(	NULL
Oncogene	NULL
Science	NULL
)	NULL
was	NULL
used	NULL
,	NULL
and	NULL
detection	NULL
was	NULL
carried	NULL
out	NULL
with	NULL
peroxidase-labeled	NULL
anti-mouse	NULL
immunoglobulin	NULL
G	NULL
(	NULL
Kirkegaard	NULL
and	NULL
Perry	NULL
Labo-ratories	NULL
,	NULL
Inc.	NULL
)	NULL
by	NULL
using	NULL
the	NULL
ECL	NULL
system	NULL
(	NULL
Amersham	NULL
.	NULL
)	NULL

As	NULL
is	NULL
evident	NULL
from	NULL
Fig	NULL
.	NULL

1A	NULL
,	NULL
EBV	NULL
infection	NULL
of	NULL
resting	NULL
B	NULL
cells	NULL
increased	NULL
p53	NULL
levels	NULL
beginning	NULL
at	NULL
approximately	NULL
24	NULL
h	NULL
after	NULL
infection	NULL
,	NULL
a	NULL
time	NULL
which	NULL
antedates	NULL
EBV-induced	NULL
cellular	NULL
DNA	NULL
synthesis	NULL
by	NULL
at	NULL
least	NULL
24	NULL
h	NULL
(	NULL
references	NULL
2	NULL
and	NULL
42	NULL
,	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Peak	NULL
p53	NULL
levels	NULL
(	NULL
approximately	NULL
10-fold	NULL
greater	NULL
than	NULL
those	NULL
of	NULL
resting	NULL
B	NULL
cells	NULL
)	NULL
occurred	NULL
4	NULL
to	NULL
5	NULL
days	NULL
after	NULL
EBV	NULL
infection	NULL
in	NULL
a	NULL
number	NULL
of	NULL
experiments	NULL
of	NULL
this	NULL
type	NULL
.	NULL

After	NULL
this	NULL
time	NULL
,	NULL
p53	NULL
levels	NULL
declined	NULL
slightly	NULL
and	NULL
then	NULL
remained	NULL
unchanged	NULL
for	NULL
at	NULL
least	NULL
5	NULL
months	NULL
,	NULL
and	NULL
probably	NULL
indefinitely	NULL
,	NULL
since	NULL
the	NULL
levels	NULL
at	NULL
this	NULL
time	NULL
point	NULL
were	NULL
comparable	NULL
to	NULL
those	NULL
in	NULL
the	NULL
LCL	NULL
preparations	NULL
which	NULL
have	NULL
been	NULL
examined	NULL
.	NULL

Uninfected	NULL
resting	NULL
B	NULL
cells	NULL
incubated	NULL
for	NULL
6	NULL
days	NULL
showed	NULL
no	NULL
changes	NULL
in	NULL
p53	NULL
levels	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
despite	NULL
the	NULL
slow	NULL
progressive	NULL
death	NULL
of	NULL
the	NULL
cells	NULL
(	NULL
approximately	NULL
50	NULL
%	NULL
cell	NULL
death	NULL
by	NULL
6	NULL
days	NULL
)	NULL
,	NULL
confirming	NULL
that	NULL
the	NULL
increase	NULL
in	NULL
p53	NULL
levels	NULL
is	NULL
EBV	NULL
specific	NULL
.	NULL

While	NULL
these	NULL
studies	NULL
were	NULL
in	NULL
progress	NULL
,	NULL
two	NULL
other	NULL
groups	NULL
reported	NULL
that	NULL
p53	NULL
levels	NULL
increase	NULL
to	NULL
peak	NULL
levels	NULL
several	NULL
days	NULL
after	NULL
primary	NULL
EBV	NULL
infection	NULL
(	NULL
4	NULL
,	NULL
53	NULL
)	NULL
,	NULL
data	NULL
which	NULL
are	NULL
comparable	NULL
to	NULL
the	NULL
present	NULL
results	NULL
.	NULL

One	NULL
of	NULL
these	NULL
studies	NULL
reported	NULL
that	NULL
elevated	NULL
p53	NULL
levels	NULL
were	NULL
maintained	NULL
(	NULL
4	NULL
)	NULL
,	NULL
which	NULL
is	NULL
in	NULL
agreement	NULL
with	NULL
our	NULL
results	NULL
,	NULL
while	NULL
the	NULL
other	NULL
found	NULL
that	NULL
p53	NULL
levels	NULL
progressively	NULL
declined	NULL
and	NULL
became	NULL
undetectable	NULL
in	NULL
LCL	NULL
4	NULL
months	NULL
after	NULL
infection	NULL
(	NULL
53	NULL
)	NULL
;	NULL
the	NULL
reasons	NULL
for	NULL
these	NULL
differences	NULL
are	NULL
not	NULL
apparent	NULL
.	NULL

Several	NULL
DNA	NULL
tumor	NULL
viruses	NULL
,	NULL
including	NULL
simian	NULL
virus	NULL
40	NULL
,	NULL
adenovirus	NULL
type	NULL
5	NULL
,	NULL
and	NULL
human	NULL
papillomavirus	NULL
types	NULL
16	NULL
and	NULL
18	NULL
,	NULL
encode	NULL
proteins	NULL
which	NULL
bind	NULL
to	NULL
,	NULL
dysregulate	NULL
,	NULL
and/or	NULL
inactivate	NULL
p53	NULL
(	NULL
30	NULL
,	NULL
31	NULL
,	NULL
46	NULL
,	NULL
48	NULL
,	NULL
60	NULL
,	NULL
65	NULL
)	NULL
.	NULL

EBV	NULL
,	NULL
like	NULL
these	NULL
viruses	NULL
,	NULL
overcomes	NULL
normal	NULL
cellular	NULL
regulatory	NULL
mechanisms	NULL
,	NULL
some	NULL
of	NULL
which	NULL
are	NULL
p53	NULL
dependent	NULL
,	NULL
leading	NULL
to	NULL
immortal	NULL
growth	NULL
and	NULL
the	NULL
prevention	NULL
of	NULL
normal	NULL
cell	NULL
death	NULL
.	NULL

With	NULL
regard	NULL
to	NULL
p53	NULL
and	NULL
EBV	NULL
,	NULL
it	NULL
has	NULL
also	NULL
been	NULL
reported	NULL
that	NULL
EBV	NULL
nuclear	NULL
antigen	NULL
LP	NULL
(	NULL
EBNA-LP	NULL
)	NULL
,	NULL
a	NULL
latent	NULL
EBV	NULL
gene	NULL
product	NULL
(	NULL
54	NULL
)	NULL
,	NULL
and	NULL
the	NULL
protein	NULL
encoded	NULL
by	NULL
the	NULL
4850	NULL
NOTES	NULL
A	NULL
Days	NULL
after	NULL
infection	NULL
aji	NULL
0	NULL
1	NULL
B	NULL
_	NULL
Days	NULL
after	NULL
infection	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
12	NULL
20	NULL
£4	NULL
”	NULL
th	NULL
vm	NULL
woe	NULL
mes	NULL
foes	NULL
nll	NULL
<	NULL
-	NULL
153	NULL
o	NULL
0	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
3	NULL
@	NULL
Sieg	NULL
.	NULL

gttemis	NULL
4—mdm	NULL
'	NULL
2	NULL
(	NULL
Days	NULL
after	NULL
infection	NULL
0	NULL
_	NULL
1	NULL
2	NULL
4	NULL
_	NULL
6	NULL
7	NULL
F	NULL
--	NULL
-	NULL
$	NULL
89	NULL
3	NULL
y	NULL
i	NULL
gee	NULL
<	NULL
-	NULL
p53	NULL
P3HR1	NULL
-	NULL
P3HR1	NULL
-	NULL
P3HR1	NULL
L____J	NULL
B95-8	NULL
-	NULL
B95-8	NULL
B95-8	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

EBV	NULL
infection	NULL
of	NULL
purified	NULL
resting	NULL
human	NULL
B	NULL
cells	NULL
increases	NULL
cellular	NULL
levels	NULL
of	NULL
transcriptionally	NULL
active	NULL
p53	NULL
and	NULL
is	NULL
dependent	NULL
on	NULL
viral	NULL
gene	NULL
expression	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Total	NULL
cellular	NULL
extracts	NULL
from	NULL
5	NULL
X	NULL
10°	NULL
cells	NULL
were	NULL
prepared	NULL
at	NULL
various	NULL
times	NULL
after	NULL
infection	NULL
with	NULL
EBV	NULL
strain	NULL
B95-8	NULL
and	NULL
assessed	NULL
for	NULL
p53	NULL
protein	NULL
by	NULL
the	NULL
Western	NULL
blotting	NULL
procedure	NULL
with	NULL
the	NULL
DO-1	NULL
p53	NULL
monoclonal	NULL
antibody	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Western	NULL
blotting	NULL
studies	NULL
of	NULL
mdm-2	NULL
expression	NULL
at	NULL
various	NULL
times	NULL
after	NULL
infection	NULL
,	NULL
using	NULL
a	NULL
monoclonal	NULL
antibody	NULL
directed	NULL
against	NULL
mdm-2	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Western	NULL
blotting	NULL
studies	NULL
of	NULL
p53	NULL
expression	NULL
at	NULL
various	NULL
times	NULL
after	NULL
incubation	NULL
of	NULL
resting	NULL
B	NULL
cells	NULL
with	NULL
EBV	NULL
strain	NULL
B95-8	NULL
or	NULL
P3HR1	NULL
.	NULL

m	NULL
*	NULL
BZLF-1	NULL
gene	NULL
,	NULL
a	NULL
lytic-cycle	NULL
protein	NULL
,	NULL
bind	NULL
pS3	NULL
(	NULL
66	NULL
)	NULL
,	NULL
but	NULL
these	NULL
studies	NULL
have	NULL
not	NULL
been	NULL
confirmed	NULL
and	NULL
the	NULL
functional	NULL
consequences	NULL
of	NULL
such	NULL
interactions	NULL
have	NULL
not	NULL
been	NULL
examined	NULL
.	NULL

In	NULL
the	NULL
present	NULL
studies	NULL
,	NULL
we	NULL
assessed	NULL
expression	NULL
of	NULL
mdm-2	NULL
and	NULL
p21/	NULL
WAFL	NULL
,	NULL
two	NULL
cellular	NULL
genes	NULL
which	NULL
are	NULL
transcriptionally	NULL
activated	NULL
by	NULL
wt	NULL
p53	NULL
(	NULL
10	NULL
,	NULL
63	NULL
)	NULL
,	NULL
during	NULL
the	NULL
early	NULL
stages	NULL
of	NULL
EBV	NULL
infection	NULL
of	NULL
resting	NULL
human	NULL
B	NULL
cells	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
the	NULL
Western	NULL
blotting	NULL
study	NULL
with	NULL
mdm-2	NULL
monoclonal	NULL
antibody	NULL
(	NULL
Oncogene	NULL
Science	NULL
)	NULL
depicted	NULL
in	NULL
Fig	NULL
.	NULL

1B	NULL
,	NULL
mdm-2	NULL
,	NULL
which	NULL
was	NULL
undetectable	NULL
in	NULL
purified	NULL
resting	NULL
human	NULL
B	NULL
cells	NULL
,	NULL
increased	NULL
with	NULL
the	NULL
same	NULL
time	NULL
course	NULL
as	NULL
p53	NULL
after	NULL
EBV	NULL
infection	NULL
.	NULL

The	NULL
other	NULL
p53-induced	NULL
gene	NULL
,	NULL
p21/	NULL
WAF1	NULL
,	NULL
behaved	NULL
similarly	NULL
;	NULL
p21/WAF1	NULL
mRNA	NULL
levels	NULL
,	NULL
which	NULL
were	NULL
very	NULL
low	NULL
in	NULL
resting	NULL
B	NULL
cells	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
reverse	NULL
transcription-PCR	NULL
followed	NULL
by	NULL
densitometry	NULL
,	NULL
increased	NULL
68-fold	NULL
(	NULL
adjusted	NULL
for	NULL
a	NULL
modest	NULL
increase	NULL
in	NULL
rpL32	NULL
mRNA	NULL
levels	NULL
)	NULL
5	NULL
days	NULL
after	NULL
EBV	NULL
infection	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
findings	NULL
indicate	NULL
that	NULL
the	NULL
p53	NULL
induced	NULL
by	NULL
EBV	NULL
is	NULL
transcriptionally	NULL
active	NULL
.	NULL

More	NULL
importantly	NULL
,	NULL
they	NULL
show	NULL
that	NULL
the	NULL
earliest	NULL
stages	NULL
of	NULL
EBV	NULL
infection	NULL
and	NULL
transformation	NULL
of	NULL
resting	NULL
B	NULL
cells	NULL
are	NULL
not	NULL
dependent	NULL
on	NULL
J.	NULL
ViroL	NULL
.	NULL

p53	NULL
inactivation	NULL
by	NULL
an	NULL
EBV	NULL
latent	NULL
gene	NULL
product	NULL
or	NULL
a	NULL
cellular	NULL
protein	NULL
expressed	NULL
during	NULL
infection	NULL
;	NULL
similar	NULL
conclusions	NULL
have	NULL
recently	NULL
been	NULL
reached	NULL
by	NULL
other	NULL
investigators	NULL
(	NULL
4	NULL
,	NULL
53	NULL
)	NULL
.	NULL

The	NULL
EBV-induced	NULL
increase	NULL
in	NULL
p53	NULL
levels	NULL
in	NULL
resting	NULL
B	NULL
cells	NULL
is	NULL
dependent	NULL
on	NULL
viral	NULL
gene	NULL
expression	NULL
.	NULL

Binding	NULL
of	NULL
ligands	NULL
to	NULL
the	NULL
CD21	NULL
EBV	NULL
receptor	NULL
on	NULL
the	NULL
cell	NULL
surface	NULL
triggers	NULL
intracellular	NULL
signaling	NULL
pathways	NULL
which	NULL
modulate	NULL
B-cell	NULL
activation	NULL
(	NULL
13	NULL
,	NULL
38	NULL
)	NULL
.	NULL

In	NULL
order	NULL
to	NULL
determine	NULL
whether	NULL
the	NULL
increased	NULL
p53	NULL
levels	NULL
observed	NULL
after	NULL
EBV	NULL
infection	NULL
of	NULL
resting	NULL
B	NULL
cells	NULL
reflected	NULL
CD21-initiated	NULL
signal	NULL
transduction	NULL
events	NULL
or	NULL
instead	NULL
were	NULL
dependent	NULL
on	NULL
viral	NULL
gene	NULL
expression	NULL
,	NULL
purified	NULL
resting	NULL
B	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
EBV	NULL
strain	NULL
P3HR1	NULL
(	NULL
37	NULL
)	NULL
;	NULL
this	NULL
EBV	NULL
strain	NULL
,	NULL
although	NULL
lacking	NULL
the	NULL
ability	NULL
to	NULL
transform	NULL
B	NULL
cells	NULL
(	NULL
19	NULL
)	NULL
(	NULL
also	NULL
verified	NULL
here	NULL
)	NULL
,	NULL
is	NULL
able	NULL
to	NULL
transduce	NULL
signals	NULL
after	NULL
binding	NULL
to	NULL
the	NULL
B-cell	NULL
surface	NULL
(	NULL
15	NULL
,	NULL
24	NULL
)	NULL
.	NULL

EBV	NULL
strain	NULL
P3HR1	NULL
did	NULL
not	NULL
increase	NULL
p53	NULL
levels	NULL
in	NULL
purified	NULL
resting	NULL
B	NULL
cells	NULL
,	NULL
as	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1C	NULL
.	NULL

Identical	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
nontransforming	NULL
UV-irradiated	NULL
EBV	NULL
strain	NULL
B95-8	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
studies	NULL
show	NULL
that	NULL
p53	NULL
induction	NULL
is	NULL
not	NULL
due	NULL
to	NULL
triggering	NULL
of	NULL
intracellular	NULL
signaling	NULL
pathways	NULL
by	NULL
the	NULL
binding	NULL
of	NULL
EBV	NULL
to	NULL
CD21	NULL
on	NULL
the	NULL
cell	NULL
surface	NULL
.	NULL

EBNA-2	NULL
and	NULL
LMP1	NULL
independently	NULL
mediate	NULL
the	NULL
increase	NULL
in	NULL
p53	NULL
levels	NULL
after	NULL
EBV	NULL
infection	NULL
of	NULL
resting	NULL
B	NULL
cells	NULL
.	NULL

The	NULL
timing	NULL
of	NULL
the	NULL
observed	NULL
increases	NULL
in	NULL
p53	NULL
in	NULL
resting	NULL
B	NULL
cells	NULL
following	NULL
EBV	NULL
infection	NULL
suggested	NULL
that	NULL
EBNA-2	NULL
and	NULL
latent	NULL
membrane	NULL
protein	NULL
1	NULL
(	NULL
LMP1	NULL
)	NULL
might	NULL
be	NULL
involved	NULL
,	NULL
since	NULL
EBNA-2	NULL
is	NULL
first	NULL
detectable	NULL
12	NULL
to	NULL
24	NULL
h	NULL
after	NULL
infection	NULL
and	NULL
peak	NULL
LMP1	NULL
levels	NULL
are	NULL
reached	NULL
4	NULL
to	NULL
6	NULL
days	NULL
after	NULL
infection	NULL
(	NULL
1	NULL
,	NULL
2	NULL
,	NULL
42	NULL
,	NULL
50	NULL
)	NULL
.	NULL

EBNA-2	NULL
is	NULL
further	NULL
implicated	NULL
by	NULL
the	NULL
fact	NULL
that	NULL
P3HR1	NULL
is	NULL
a	NULL
deletion	NULL
mutant	NULL
lacking	NULL
the	NULL
gene	NULL
coding	NULL
for	NULL
EBNA-2	NULL
(	NULL
19	NULL
)	NULL
.	NULL

In	NULL
order	NULL
to	NULL
evaluate	NULL
this	NULL
possibility	NULL
,	NULL
purified	NULL
resting	NULL
human	NULL
B	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
expression	NULL
plasmids	NULL
encoding	NULL
EBNA-2	NULL
(	NULL
pSGS-EBNA-2A	NULL
or	NULL
SV-EBNA-2	NULL
[	NULL
59	NULL
]	NULL
)	NULL
or	NULL
LMP1	NULL
(	NULL
pSV2gpMTLM	NULL
[	NULL
58	NULL
]	NULL
)	NULL
,	NULL
with	NULL
both	NULL
of	NULL
these	NULL
plasmids	NULL
together	NULL
,	NULL
or	NULL
with	NULL
control	NULL
plasmids	NULL
pSV2gpt	NULL
(	NULL
35	NULL
)	NULL
and	NULL
pSGS	NULL
(	NULL
17	NULL
)	NULL
by	NULL
electroporation	NULL
in	NULL
a	NULL
Bio-Rad	NULL
Gene	NULL
Pulser	NULL
(	NULL
10	NULL
ug	NULL
of	NULL
DNA	NULL
,	NULL
balanced	NULL
by	NULL
addition	NULL
of	NULL
vector	NULL
DNA	NULL
;	NULL
4-mm-gap	NULL
cuvettes	NULL
;	NULL
320	NULL
V	NULL
and	NULL
960	NULL
uF	NULL
)	NULL
.	NULL

Trivial	NULL
expression	NULL
of	NULL
transfected	NULL
plasmid	NULL
DNAs	NULL
in	NULL
resting	NULL
B	NULL
cells	NULL
was	NULL
observed	NULL
unless	NULL
the	NULL
cells	NULL
were	NULL
pretreated	NULL
with	NULL
recombinant	NULL
gp105	NULL
,	NULL
the	NULL
ligand-binding	NULL
portion	NULL
of	NULL
gp350/220	NULL
(	NULL
55	NULL
)	NULL
,	NULL
in	NULL
immobilized	NULL
form	NULL
on	NULL
tissue	NULL
culture	NULL
dishes	NULL
(	NULL
40	NULL
ng/ml	NULL
for	NULL
20	NULL
h	NULL
)	NULL
,	NULL
as	NULL
recently	NULL
reported	NULL
for	NULL
the	NULL
complete	NULL
gp350/220	NULL
glycoprotein	NULL
(	NULL
50	NULL
)	NULL
.	NULL

Under	NULL
such	NULL
conditions	NULL
,	NULL
the	NULL
transfection	NULL
efficiency	NULL
increased	NULL
to	NULL
2	NULL
to	NULL
5	NULL
%	NULL
,	NULL
as	NULL
assessed	NULL
with	NULL
a	NULL
transfected	NULL
pCMV-B-gal	NULL
plasmid	NULL
.	NULL

Cadmium	NULL
chloride	NULL
(	NULL
6	NULL
wM	NULL
)	NULL
was	NULL
added	NULL
24	NULL
h	NULL
posttransfection	NULL
for	NULL
induction	NULL
,	NULL
and	NULL
total	NULL
RNA	NULL
was	NULL
prepared	NULL
(	NULL
approximately	NULL
2	NULL
%	NULL
10°	NULL
cells	NULL
per	NULL
sample	NULL
;	NULL
Micro-scale	NULL
Total	NULL
RNA	NULL
Separator	NULL
Kit	NULL
,	NULL
Clontech	NULL
Laboratories	NULL
)	NULL
from	NULL
live	NULL
cells	NULL
by	NULL
the	NULL
use	NULL
of	NULL
Ficoll	NULL
72	NULL
h	NULL
after	NULL
transfection	NULL
.	NULL

Reverse	NULL
transcription-PCR	NULL
(	NULL
10	NULL
ug	NULL
of	NULL
cDNA	NULL
per	NULL
sample	NULL
)	NULL
(	NULL
32	NULL
)	NULL
was	NULL
employed	NULL
to	NULL
assess	NULL
the	NULL
expression	NULL
of	NULL
p53	NULL
,	NULL
EBNA-2	NULL
,	NULL
LMP1	NULL
,	NULL
and	NULL
rpL32	NULL
,	NULL
a	NULL
housekeeping	NULL
gene	NULL
.	NULL

Upstream	NULL
and	NULL
downstream	NULL
primers	NULL
and	NULL
amplified	NULL
fragment	NULL
lengths	NULL
were	NULL
as	NULL
follows	NULL
:	NULL
5-GTTGGCTCTGACTGTACCA-3	NULL
'	NULL
and	NULL
5-AAG	NULL
GCCTCATTCAGCTCTC-3	NULL
'	NULL
(	NULL
371	NULL
bp	NULL
)	NULL
for	NULL
p53	NULL
;	NULL
5	NULL
GATGCCTGGACA-3	NULL
'	NULL
and	NULL
5-AGGCCITTGGTGGCATCAT	NULL
G-3	NULL
'	NULL
(	NULL
348	NULL
bp	NULL
)	NULL
for	NULL
EBNA-2	NULL
;	NULL
5-GGTCTCTGGATCTACTTA	NULL
TT-3	NULL
'	NULL
and	NULL
5-TCCACTCACGAGCAGGAGGT-3	NULL
'	NULL
(	NULL
330	NULL
bp	NULL
)	NULL
for	NULL
LMP1	NULL
;	NULL
and	NULL
5'-ATGAATTCTCCTTCTCGGCATCATGG	NULL
C-3	NULL
'	NULL
and	NULL
5'-CGGGATCCAGTTACGCTTAATT-3	NULL
'	NULL
(	NULL
133	NULL
bp	NULL
)	NULL
for	NULL
rpL32	NULL
.	NULL

PCR	NULL
products	NULL
,	NULL
after	NULL
electrophoresis	NULL
on	NULL
1	NULL
%	NULL
agarose	NULL
gels	NULL
,	NULL
were	NULL
visualized	NULL
with	NULL
ethidium	NULL
bromide	NULL
.	NULL

As	NULL
is	NULL
evident	NULL
from	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
EBNA-2	NULL
expression	NULL
in	NULL
purified	NULL
resting	NULL
human	NULL
B	NULL
cells	NULL
increased	NULL
p53	NULL
transcription	NULL
;	NULL
densitomet-ric	NULL
analysis	NULL
documented	NULL
a	NULL
twofold	NULL
increase	NULL
.	NULL

A	NULL
5-fold	NULL
increase	NULL
occurred	NULL
in	NULL
the	NULL
LMP1-transfected	NULL
cells	NULL
,	NULL
and	NULL
a	NULL
10-fold	NULL
increase	NULL
was	NULL
found	NULL
in	NULL
primary	NULL
B	NULL
cells	NULL
transfected	NULL
with	NULL
both	NULL
latent	NULL
genes	NULL
.	NULL

voL	NULL
.	NULL

70	NULL
,	NULL
1996	NULL
LMP1+EBNA2A	NULL
<	NULL
C	NULL
o	NULL
<	NULL
C	NULL
22.	NULL
o	NULL
LL	NULL
wud	NULL
med	NULL
|	NULL
4-	NULL
EBNAZA	NULL
toe	NULL
<	NULL
-	NULL
rpL32	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

EBNA-2	NULL
and	NULL
LMP1	NULL
independently	NULL
mediate	NULL
the	NULL
increase	NULL
in	NULL
p53	NULL
levels	NULL
after	NULL
EBV	NULL
infection	NULL
of	NULL
resting	NULL
B	NULL
cells	NULL
.	NULL

Shown	NULL
are	NULL
the	NULL
results	NULL
of	NULL
reverse	NULL
transcription-PCR	NULL
analysis	NULL
of	NULL
p53	NULL
,	NULL
EBNA-2	NULL
,	NULL
LMP1	NULL
,	NULL
and	NULL
rpL32	NULL
expression	NULL
72	NULL
h	NULL
after	NULL
transfection	NULL
,	NULL
by	NULL
electroporation	NULL
,	NULL
of	NULL
gp105-pretreated	NULL
resting	NULL
B	NULL
cells	NULL
.	NULL

Vectors	NULL
,	NULL
cells	NULL
transfected	NULL
with	NULL
both	NULL
pSV2gpt	NULL
and	NULL
pSGS	NULL
.	NULL

These	NULL
are	NULL
previously	NULL
unreported	NULL
actions	NULL
of	NULL
these	NULL
EBV	NULL
latent	NULL
genes	NULL
.	NULL

EBNA-2	NULL
and	NULL
LMP1	NULL
upregulate	NULL
p53	NULL
by	NULL
activating	NULL
the	NULL
NF-KB	NULL
transcription	NULL
factor	NULL
.	NULL

Recent	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
LMP1	NULL
activates	NULL
the	NULL
NF-KB	NULL
transcription	NULL
factor	NULL
(	NULL
23	NULL
,	NULL
34	NULL
,	NULL
44	NULL
)	NULL
,	NULL
leading	NULL
to	NULL
the	NULL
expression	NULL
of	NULL
several	NULL
genes	NULL
,	NULL
including	NULL
the	NULL
long	NULL
terminal	NULL
repeat	NULL
(	NULL
LTR	NULL
)	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HIV-1	NULL
)	NULL
(	NULL
18	NULL
)	NULL
;	NULL
A20	NULL
,	NULL
a	NULL
zinc	NULL
finger	NULL
protein	NULL
which	NULL
affords	NULL
protection	NULL
against	NULL
the	NULL
cytotoxic	NULL
actions	NULL
of	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
(	NULL
28	NULL
)	NULL
;	NULL
and	NULL
IxB-related	NULL
genes	NULL
(	NULL
20	NULL
)	NULL
.	NULL

A	NULL
single	NULL
study	NULL
reported	NULL
that	NULL
EBNA-2	NULL
activates	NULL
the	NULL
HIV	NULL
LTR	NULL
via	NULL
NF-	NULL
«	NULL
B	NULL
induction	NULL
(	NULL
47	NULL
)	NULL
.	NULL

It	NULL
has	NULL
also	NULL
been	NULL
reported	NULL
that	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
mediates	NULL
increased	NULL
p53	NULL
levels	NULL
by	NULL
activating	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
which	NULL
then	NULL
binds	NULL
to	NULL
an	NULL
NF-	NULL
«	NULL
B	NULL
consensus	NULL
binding	NULL
site	NULL
in	NULL
the	NULL
p53	NULL
promoter	NULL
(	NULL
62	NULL
)	NULL
.	NULL

Because	NULL
of	NULL
these	NULL
reports	NULL
,	NULL
we	NULL
evaluated	NULL
the	NULL
possibility	NULL
that	NULL
EBNA-2	NULL
and	NULL
LMP1	NULL
increase	NULL
p53	NULL
levels	NULL
during	NULL
the	NULL
early	NULL
stages	NULL
of	NULL
infection	NULL
via	NULL
NF-xB	NULL
activation	NULL
.	NULL

In	NULL
these	NULL
studies	NULL
,	NULL
293	NULL
primary	NULL
human	NULL
embryonal	NULL
kidney	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
EBNA-2	NULL
,	NULL
LMP1	NULL
,	NULL
or	NULL
EBNA-2	NULL
plus	NULL
LMP1	NULL
expression	NULL
plasmids	NULL
by	NULL
the	NULL
lipofectamine	NULL
procedure	NULL
(	NULL
Gibco	NULL
BRL	NULL
Life	NULL
Technolo-gies	NULL
,	NULL
Inc.	NULL
)	NULL
.	NULL

One	NULL
microgram	NULL
of	NULL
each	NULL
plasmid	NULL
was	NULL
used	NULL
for	NULL
all	NULL
combinations	NULL
,	NULL
and	NULL
the	NULL
vectors	NULL
(	NULL
pSV2gpt	NULL
and	NULL
pSG5	NULL
)	NULL
were	NULL
used	NULL
to	NULL
balance	NULL
the	NULL
total	NULL
amount	NULL
of	NULL
DNA	NULL
.	NULL

Transfection	NULL
efficiencies	NULL
were	NULL
adjusted	NULL
to	NULL
the	NULL
same	NULL
values	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
pCMV-B-gal	NULL
plasmid	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
the	NULL
293	NULL
transfected	NULL
cells	NULL
expressed	NULL
EBNA-2	NULL
,	NULL
LMP1	NULL
,	NULL
or	NULL
both	NULL
latent	NULL
genes	NULL
,	NULL
as	NULL
assessed	NULL
by	NULL
the	NULL
West-etn	NULL
blotting	NULL
technique	NULL
(	NULL
using	NULL
EBNA-2	NULL
monoclonal	NULL
antibody	NULL
PE2	NULL
[	NULL
64	NULL
]	NULL
,	NULL
LMP1	NULL
monoclonal	NULL
antibody	NULL
S12	NULL
[	NULL
33	NULL
]	NULL
,	NULL
peroxidase-labeled	NULL
anti-mouse	NULL
immunoglobulin	NULL
G	NULL
,	NULL
and	NULL
the	NULL
ECL	NULL
system	NULL
)	NULL
72	NULL
h	NULL
after	NULL
transfection	NULL
.	NULL

Gel	NULL
shift	NULL
assays	NULL
were	NULL
carried	NULL
out	NULL
to	NULL
determine	NULL
whether	NULL
EBNA-2	NULL
and	NULL
LMP1	NULL
induced	NULL
NF-kB-like	NULL
nuclear	NULL
proteins	NULL
.	NULL

For	NULL
these	NULL
studies	NULL
,	NULL
nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
49	NULL
)	NULL
and	NULL
10	NULL
ug	NULL
of	NULL
protein	NULL
per	NULL
sample	NULL
was	NULL
evaluated	NULL
for	NULL
the	NULL
ability	NULL
to	NULL
bind	NULL
a	NULL
double-stranded	NULL
end-labeled	NULL
oligonucleotide	NULL
duplicating	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
in	NULL
the	NULL
NOTES	NULL
4851	NULL
|	NULL
44	NULL
a	NULL
+4	NULL
$	NULL
&	NULL
S	NULL
LS	NULL
_	NULL
U	NULL
$	NULL
35	NULL
§	NULL
30	NULL
9	NULL
A	NULL
mame	NULL
swe	NULL
<	NULL
-	NULL
LMP	NULL
]	NULL
LMP1	NULL
-	NULL
o	NULL
$	NULL
o-	NULL
oto	NULL
4	NULL
+	NULL
#	NULL
EBNA2ZA	NULL
oe	NULL
ae	NULL
e	NULL
e	NULL
ae	NULL
Competitor	NULL
p53wt	NULL
-	NULL
-	NULL
-	NULL
-	NULL
We	NULL
-	NULL
p53mut	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
c-	NULL
4	NULL
NF-xB	NULL
=	NULL
e	NULL
-	NULL
-	NULL
pe	NULL
B	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

LMP1	NULL
and	NULL
EBNA-2A	NULL
expressed	NULL
in	NULL
transfected	NULL
293	NULL
cells	NULL
trigger	NULL
the	NULL
expression	NULL
of	NULL
nuclear	NULL
proteins	NULL
which	NULL
bind	NULL
to	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
in	NULL
the	NULL
p53	NULL
promoter	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Western	NULL
blotting	NULL
analysis	NULL
of	NULL
EBNA-2	NULL
and	NULL
LMP1	NULL
expression	NULL
in	NULL
293	NULL
cells	NULL
72	NULL
h	NULL
after	NULL
transfection	NULL
,	NULL
using	NULL
the	NULL
PE2	NULL
and	NULL
$	NULL
12	NULL
monoclonal	NULL
antibodies	NULL
to	NULL
EBNA-2	NULL
and	NULL
LMP1	NULL
,	NULL
respectively	NULL
.	NULL

Vectors	NULL
,	NULL
cells	NULL
transfected	NULL
with	NULL
both	NULL
pSV2gpt	NULL
and	NULL
pSG5	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Gel	NULL
shift	NULL
analysis	NULL
of	NULL
nuclear	NULL
proteins	NULL
binding	NULL
to	NULL
the	NULL
wt	NULL
NF-	NULL
«	NULL
B	NULL
sequence	NULL
in	NULL
the	NULL
p53	NULL
promoter	NULL
72	NULL
h	NULL
after	NULL
transfection	NULL
of	NULL
293	NULL
cells	NULL
with	NULL
EBNA-2	NULL
,	NULL
LMP1	NULL
,	NULL
or	NULL
both	NULL
EBNA-2	NULL
and	NULL
LMP1	NULL
.	NULL

Competition	NULL
studies	NULL
were	NULL
carried	NULL
out	NULL
with	NULL
50-fold	NULL
excesses	NULL
of	NULL
the	NULL
unlabeled	NULL
wt	NULL
NF-	NULL
«	NULL
B	NULL
p53	NULL
probe	NULL
,	NULL
a	NULL
mutant	NULL
(	NULL
mut	NULL
)	NULL
p33	NULL
probe	NULL
,	NULL
and	NULL
a	NULL
consensus	NULL
probe	NULL
(	NULL
NF-	NULL
«	NULL
B	NULL
)	NULL
.	NULL

p53	NULL
promoter	NULL
(	NULL
+49	NULL
to	NULL
+68	NULL
,	NULL
5-TGGGATTGGGACTTTCC	NULL
CCT-3	NULL
'	NULL
)	NULL
.	NULL

Competition	NULL
studies	NULL
were	NULL
performed	NULL
with	NULL
50-fold	NULL
excesses	NULL
of	NULL
the	NULL
unlabeled	NULL
wt	NULL
oligonucleotide	NULL
,	NULL
an	NULL
oligonucleotide	NULL
with	NULL
mutations	NULL
in	NULL
the	NULL
p53	NULL
NF-kB	NULL
site	NULL
(	NULL
5'-TGGGATTAT	NULL
CACTTTTAAGCT-3	NULL
'	NULL
;	NULL
mutated	NULL
positions	NULL
are	NULL
underlined	NULL
)	NULL
and	NULL
a	NULL
canonical	NULL
NF-kB	NULL
consensus	NULL
sequence	NULL
(	NULL
5'-AGTTGAGGG	NULL
GACTTTCCCAGGC-3	NULL
'	NULL
;	NULL
Promega	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3B	NULL
,	NULL
EBNA-2	NULL
and	NULL
,	NULL
to	NULL
a	NULL
greater	NULL
extent	NULL
,	NULL
LMP1	NULL
induced	NULL
the	NULL
appearance	NULL
of	NULL
nuclear	NULL
proteins	NULL
which	NULL
bound	NULL
to	NULL
an	NULL
oligonucleotide	NULL
containing	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
in	NULL
the	NULL
p53	NULL
promoter	NULL
,	NULL
and	NULL
an	NULL
additive	NULL
effect	NULL
was	NULL
observed	NULL
in	NULL
293	NULL
cells	NULL
expressing	NULL
both	NULL
proteins	NULL
.	NULL

The	NULL
binding	NULL
was	NULL
specific	NULL
,	NULL
as	NULL
it	NULL
was	NULL
fully	NULL
inhibited	NULL
by	NULL
the	NULL
homologous	NULL
oligonucleotide	NULL
and	NULL
by	NULL
an	NULL
oligonucleotide	NULL
containing	NULL
the	NULL
4852	NULL
NOTES	NULL
Reporter	NULL
___	NULL
Effector	NULL
___	NULL
Percent	NULL
Fold-stimulation	NULL
relative	NULL
Plasmid	NULL
_	NULL
LMP1	NULL
-	NULL
EBNAZA	NULL
Acetylation	NULL
to	NULL
vector	NULL
control	NULL
pMSCAT	NULL
o	NULL
5s	NULL
10	NULL
16	NULL
2o	NULL
ps	NULL
30	NULL
as	NULL
40	NULL
+	NULL
=	NULL
=	NULL
©	NULL
®	NULL
5.7	NULL
+	NULL
+	NULL
~	NULL
©	NULL
®	NULL
10.6	NULL
-	NULL
+	NULL
+	NULL
©	NULL
+	NULL
=	NULL
+	NULL
©	NULL
2.9	NULL
+	NULL
¥	NULL
+	NULL
%	NULL
s	NULL
%	NULL
20.5	NULL
pO.5CAT	NULL
a	NULL
+	NULL
=	NULL
-	NULL
e	NULL
~	NULL
@	NULL
4.5	NULL
+	NULL
+	NULL
=	NULL
e	NULL
°	NULL
®	NULL
§3.2	NULL
=	NULL
+	NULL
+	NULL
@	NULL
+	NULL
=	NULL
+	NULL
e	NULL
~	NULL
©	NULL
17.3	NULL
+	NULL
+	NULL
+	NULL
*	NULL
#	NULL
@	NULL
80.1	NULL
I	NULL
+	NULL
=	NULL
=	NULL
©	NULL
2.2	NULL
+	NULL
+	NULL
=	NULL
0	NULL
o	NULL
®	NULL
41.6	NULL
-	NULL
+	NULL
+	NULL
©	NULL
+	NULL
-	NULL
4	NULL
®	NULL
©	NULL
e	NULL
11.0	NULL
+	NULL
+	NULL
+	NULL
o	NULL
se	NULL
83.3	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

EBNA-2	NULL
and	NULL
LMP1	NULL
independently	NULL
activate	NULL
the	NULL
p53	NULL
promoter	NULL
via	NULL
NF-xB	NULL
.	NULL

CAT	NULL
assays	NULL
were	NULL
performed	NULL
on	NULL
293	NULL
cells	NULL
72	NULL
h	NULL
after	NULL
cotransfection	NULL
with	NULL
the	NULL
pS3	NULL
reporter	NULL
plasmid	NULL
pO.5CAT	NULL
(	NULL
containing	NULL
an	NULL
intact	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
)	NULL
or	NULL
pMS5CAT	NULL
(	NULL
containing	NULL
a	NULL
mutant	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
)	NULL
,	NULL
together	NULL
with	NULL
EBNA-2	NULL
,	NULL
LMP1	NULL
,	NULL
or	NULL
EBNA-2	NULL
plus	NULL
LMP1	NULL
expression	NULL
plasmids	NULL
.	NULL

The	NULL
HIV	NULL
LTR	NULL
construct	NULL
containing	NULL
two	NULL
NF-kB	NULL
sites	NULL
,	NULL
pU3R-III-CAT	NULL
,	NULL
was	NULL
used	NULL
as	NULL
a	NULL
control	NULL
.	NULL

Percent	NULL
acetylation	NULL
was	NULL
quantitated	NULL
by	NULL
scanning	NULL
with	NULL
a	NULL
PhosphorImager	NULL
.	NULL

NF-kB	NULL
consensus	NULL
sequence	NULL
but	NULL
not	NULL
by	NULL
an	NULL
oligonucleotide	NULL
containing	NULL
a	NULL
mutated	NULL
NF-kB	NULL
sequence	NULL
,	NULL
as	NULL
depicted	NULL
in	NULL
Fig	NULL
.	NULL

3B	NULL
.	NULL

In	NULL
order	NULL
to	NULL
determine	NULL
whether	NULL
activation	NULL
of	NULL
the	NULL
p53	NULL
promoter	NULL
was	NULL
NF-kB	NULL
dependent	NULL
,	NULL
293	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
the	NULL
EBNA-2	NULL
,	NULL
LMP1	NULL
,	NULL
or	NULL
EBNA-2	NULL
plus	NULL
LMP1	NULL
expression	NULL
plasmids	NULL
together	NULL
with	NULL
one	NULL
of	NULL
two	NULL
chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
reporter	NULL
plasmids	NULL
:	NULL
pQ.5CAT	NULL
or	NULL
pMSCAT	NULL
(	NULL
62	NULL
)	NULL
.	NULL

The	NULL
p0.5CAT	NULL
construct	NULL
contains	NULL
approximately	NULL
500	NULL
bp	NULL
of	NULL
the	NULL
wt	NULL
p53	NULL
promoter	NULL
(	NULL
-320	NULL
to	NULL
+216	NULL
)	NULL
,	NULL
as	NULL
does	NULL
the	NULL
pMSCAT	NULL
con-struct	NULL
;	NULL
however	NULL
,	NULL
in	NULL
the	NULL
latter	NULL
,	NULL
the	NULL
sequence	NULL
GGGACTTTCCC	NULL
}	NULL
,	NULL
which	NULL
contains	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
consensus	NULL
binding	NULL
sequence	NULL
,	NULL
has	NULL
been	NULL
mutated	NULL
to	NULL
ATCACTTTAAG	NULL
.	NULL

As	NULL
a	NULL
positive	NULL
control	NULL
,	NULL
the	NULL
pU3R-IHII-CAT	NULL
construct	NULL
(	NULL
43	NULL
)	NULL
,	NULL
which	NULL
contains	NULL
two	NULL
NF-	NULL
«	NULL
B	NULL
sites	NULL
in	NULL
the	NULL
HIV	NULL
LTR	NULL
,	NULL
was	NULL
also	NULL
cotransfected	NULL
with	NULL
EBNA-2	NULL
,	NULL
LMP1	NULL
,	NULL
or	NULL
EBNA-2	NULL
plus	NULL
LMP1	NULL
.	NULL

Transfections	NULL
were	NULL
carried	NULL
out	NULL
as	NULL
described	NULL
above	NULL
,	NULL
and	NULL
cell	NULL
extracts	NULL
were	NULL
prepared	NULL
72	NULL
h	NULL
later	NULL
.	NULL

CAT	NULL
assays	NULL
were	NULL
carried	NULL
out	NULL
using	NULL
a	NULL
CAT	NULL
enzyme	NULL
assay	NULL
system	NULL
(	NULL
Promega	NULL
)	NULL
,	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
16	NULL
)	NULL
.	NULL

The	NULL
percent	NULL
acetylation	NULL
of	NULL
thin-layer	NULL
chromatograms	NULL
was	NULL
quantitated	NULL
by	NULL
scanning	NULL
with	NULL
a	NULL
PhosphorImager	NULL
(	NULL
Molecular	NULL
Dynamics	NULL
)	NULL
.	NULL

These	NULL
assays	NULL
showed	NULL
that	NULL
the	NULL
p53CAT	NULL
promoter	NULL
construct	NULL
containing	NULL
the	NULL
wt	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
sequence	NULL
(	NULL
pO.SCAT	NULL
)	NULL
was	NULL
activated	NULL
in	NULL
cells	NULL
which	NULL
had	NULL
been	NULL
cotransfected	NULL
with	NULL
plasmids	NULL
containing	NULL
EBNA-2	NULL
,	NULL
LMP1	NULL
,	NULL
or	NULL
both	NULL
latent	NULL
genes	NULL
,	NULL
as	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

Transfectants	NULL
expressing	NULL
EBNA-2	NULL
produced	NULL
a	NULL
3.8-fold	NULL
increase	NULL
,	NULL
those	NULL
expressing	NULL
LMP1	NULL
exhibited	NULL
an	NULL
11.8-fold	NULL
increase	NULL
,	NULL
and	NULL
those	NULL
expressing	NULL
both	NULL
latent	NULL
genes	NULL
showed	NULL
a	NULL
17.8-fold	NULL
increase	NULL
in	NULL
CAT	NULL
activity	NULL
over	NULL
background	NULL
levels	NULL
.	NULL

However	NULL
,	NULL
the	NULL
p53CAT	NULL
construct	NULL
containing	NULL
the	NULL
mutated	NULL
NF-KB	NULL
site	NULL
was	NULL
not	NULL
significantly	NULL
activated	NULL
by	NULL
either	NULL
EBV	NULL
latent	NULL
gene	NULL
(	NULL
3.6-fold	NULL
maximal	NULL
increase	NULL
over	NULL
background	NULL
CAT	NULL
activity	NULL
)	NULL
,	NULL
as	NULL
seen	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

EBNA-2	NULL
,	NULL
LMP1	NULL
,	NULL
and	NULL
the	NULL
two	NULL
together	NULL
activated	NULL
the	NULL
HIV-1	NULL
LTR	NULL
(	NULL
5-	NULL
,	NULL
18.9-	NULL
,	NULL
and	NULL
37.9-fold	NULL
over	NULL
background	NULL
,	NULL
respectively	NULL
)	NULL
,	NULL
as	NULL
previously	NULL
reported	NULL
(	NULL
18	NULL
,	NULL
47	NULL
)	NULL
.	NULL

These	NULL
studies	NULL
definitively	NULL
demonstrate	NULL
that	NULL
p53	NULL
induction	NULL
by	NULL
the	NULL
EBV	NULL
latent	NULL
genes	NULL
is	NULL
mediated	NULL
via	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
.	NULL

There	NULL
are	NULL
at	NULL
least	NULL
three	NULL
possible	NULL
explanations	NULL
for	NULL
the	NULL
failure	NULL
of	NULL
the	NULL
increased	NULL
levels	NULL
of	NULL
wt	NULL
p53	NULL
induced	NULL
by	NULL
EBV	NULL
infection	NULL
to	NULL
block	NULL
cell	NULL
division	NULL
and/or	NULL
to	NULL
induce	NULL
apoptosis	NULL
,	NULL
and	NULL
they	NULL
are	NULL
not	NULL
mutually	NULL
exclusive	NULL
.	NULL

First	NULL
,	NULL
there	NULL
may	NULL
be	NULL
a	NULL
threshold	NULL
level	NULL
of	NULL
p53	NULL
J.	NULL
ViroL	NULL
.	NULL

required	NULL
for	NULL
these	NULL
effects	NULL
which	NULL
is	NULL
not	NULL
reached	NULL
during	NULL
EBV	NULL
infection	NULL
.	NULL

Second	NULL
,	NULL
downstream	NULL
events	NULL
which	NULL
mediate	NULL
p53-trig-gered	NULL
cell	NULL
cycle	NULL
arrest	NULL
or	NULL
apoptosis	NULL
may	NULL
be	NULL
blocked	NULL
by	NULL
EBV	NULL
latent	NULL
proteins	NULL
or	NULL
by	NULL
EBV-induced	NULL
cellular	NULL
proteins	NULL
.	NULL

Third	NULL
,	NULL
and	NULL
we	NULL
feel	NULL
most	NULL
likely	NULL
,	NULL
EBV-induced	NULL
increases	NULL
in	NULL
c-myc	NULL
(	NULL
7	NULL
,	NULL
22	NULL
,	NULL
26	NULL
)	NULL
or	NULL
in	NULL
other	NULL
cell	NULL
cycle-regulating	NULL
proteins	NULL
,	NULL
such	NULL
as	NULL
cyclin	NULL
D2	NULL
,	NULL
ede-2	NULL
,	NULL
or	NULL
cyclin	NULL
E	NULL
,	NULL
all	NULL
of	NULL
which	NULL
are	NULL
increased	NULL
by	NULL
EBV	NULL
infection	NULL
(	NULL
22	NULL
,	NULL
26	NULL
,	NULL
41	NULL
,	NULL
50	NULL
)	NULL
,	NULL
may	NULL
block	NULL
the	NULL
inhibitory	NULL
effects	NULL
of	NULL
elevated	NULL
p53	NULL
and	NULL
p21/WAF1	NULL
levels	NULL
and	NULL
continuously	NULL
drive	NULL
the	NULL
cells	NULL
through	NULL
normal	NULL
cell	NULL
cycle	NULL
checkpoints	NULL
.	NULL

Similar	NULL
postulates	NULL
have	NULL
been	NULL
made	NULL
by	NULL
others	NULL
to	NULL
explain	NULL
other	NULL
aspects	NULL
of	NULL
EBV	NULL
immortalization	NULL
(	NULL
3	NULL
,	NULL
22	NULL
,	NULL
26	NULL
)	NULL
.	NULL

Studies	NULL
of	NULL
the	NULL
mechanisms	NULL
involved	NULL
are	NULL
under	NULL
way	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
USPHS	NULL
grants	NULL
AI33244	NULL
and	NULL
CA532241	NULL
and	NULL
GCRC	NULL
grant	NULL
2MO1	NULL
RRO00833	NULL
.	NULL

This	NULL
is	NULL
manuscript	NULL
9806-IMM	NULL
.	NULL

We	NULL
thank	NULL
W.	NULL
Haseltine	NULL
,	NULL
E.	NULL
Kieff	NULL
,	NULL
G.	NULL
Lozano	NULL
,	NULL
J.	NULL
Sodroski	NULL
,	NULL
and	NULL
F.	NULL
Wang	NULL
for	NULL
plasmids	NULL
,	NULL
G.	NULL
Nemerow	NULL
for	NULL
recombinant	NULL
gp105	NULL
,	NULL
Bonnie	NULL
Bradt	NULL
for	NULL
technical	NULL
support	NULL
,	NULL
and	NULL
Catalina	NULL
Hope	NULL
for	NULL
assistance	NULL
with	NULL
the	NULL
manu-script	NULL
.	NULL

We	NULL
also	NULL
thank	NULL
the	NULL
Department	NULL
of	NULL
Pathology	NULL
and	NULL
the	NULL
operating	NULL
room	NULL
staff	NULL
of	NULL
San	NULL
Diego	NULL
Children	NULL
's	NULL
Hospital	NULL
and	NULL
the	NULL
Cooperative	NULL
Human	NULL
Tissue	NULL
Network	NULL
for	NULL
human	NULL
tonsil	NULL
surgical	NULL
specimens	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Alfieri	NULL
,	NULL
C.	NULL
,	NULL
M.	NULL
Birkenbach	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1991	NULL
.	NULL

Early	NULL
events	NULL
in	NULL
Epstein-Barr	NULL
virus	NULL
infection	NULL
of	NULL
human	NULL
B	NULL
lymphocytes	NULL
.	NULL

Virology	NULL
181:595-608	NULL
.	NULL

2	NULL
.	NULL

Allday	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
D.	NULL
H.	NULL
Crawford	NULL
,	NULL
and	NULL
B.	NULL
E.	NULL
Griffin	NULL
.	NULL

1989	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
latent	NULL
gene	NULL
expression	NULL
during	NULL
the	NULL
initiation	NULL
of	NULL
B	NULL
cell	NULL
immortalization	NULL
.	NULL

J.	NULL
Gen.	NULL
Virol	NULL
.	NULL

70:1755-1764	NULL
.	NULL

3	NULL
.	NULL

Allday	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
G.	NULL
J.	NULL
Inman	NULL
,	NULL
D.	NULL
H.	NULL
Crawford	NULL
,	NULL
and	NULL
P.	NULL
J.	NULL
Farrell	NULL
.	NULL

1995	NULL
.	NULL

DNA	NULL
damage	NULL
in	NULL
human	NULL
B	NULL
cells	NULL
can	NULL
induce	NULL
apoptosis	NULL
,	NULL
proceeding	NULL
from	NULL
G	NULL
;	NULL
/S	NULL
when	NULL
p53	NULL
is	NULL
transactivation	NULL
competent	NULL
and	NULL
G	NULL
;	NULL
/M	NULL
when	NULL
it	NULL
is	NULL
transactivation	NULL
defec-tive	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

14:4994-5005	NULL
.	NULL

4	NULL
.	NULL

Allday	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
A.	NULL
Sinclair	NULL
,	NULL
G.	NULL
Parker	NULL
,	NULL
D.	NULL
H.	NULL
Crawford	NULL
,	NULL
and	NULL
P.	NULL
J.	NULL
Farrell	NULL
.	NULL

1995	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
efficiently	NULL
immortalizes	NULL
human	NULL
B	NULL
cells	NULL
without	NULL
neutralizing	NULL
the	NULL
function	NULL
of	NULL
p53	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

14:1382-1391	NULL
.	NULL

5	NULL
.	NULL

Ballerini	NULL
,	NULL
P.	NULL
,	NULL
G.	NULL
Gaidano	NULL
,	NULL
J	NULL
.	NULL

Z.	NULL
Gong	NULL
,	NULL
V.	NULL
Tassi	NULL
,	NULL
G.	NULL
Saglio	NULL
,	NULL
D.	NULL
M.	NULL
Knowles	NULL
,	NULL
and	NULL
R.	NULL
Dalla-Favera	NULL
.	NULL

1993	NULL
.	NULL

Multiple	NULL
genetic	NULL
lesions	NULL
in	NULL
acquired	NULL
immunodeficiency	NULL
syndrome-related	NULL
non-Hodgkin	NULL
's	NULL
lymphoma	NULL
.	NULL

Blood	NULL
81:166-176	NULL
.	NULL

6	NULL
.	NULL

Berg	NULL
,	NULL
L.	NULL
C.	NULL
,	NULL
C.	NULL
M.	NULL
Copenhaver	NULL
,	NULL
V.	NULL
A.	NULL
Morrison	NULL
,	NULL
S.	NULL
A.	NULL
Gruber	NULL
,	NULL
D.	NULL
L.	NULL
Dunn	NULL
,	NULL
K.	NULL
Gajl-Peczalska	NULL
,	NULL
and	NULL
J.	NULL
G.	NULL
Strickler	NULL
,	NULL
1992	NULL
.	NULL

B-cell	NULL
lymphoproliferative	NULL
disorders	NULL
in	NULL
solid-organ	NULL
transplant	NULL
patients	NULL
:	NULL
detection	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
by	NULL
in	NULL
situ	NULL
hybridization	NULL
.	NULL

Hum	NULL
.	NULL

Pathol	NULL
.	NULL

23:159-163	NULL
.	NULL

7	NULL
.	NULL

Cherney	NULL
,	NULL
B.	NULL
W.	NULL
,	NULL
and	NULL
K.	NULL
Bhatia	NULL
.	NULL

1994	NULL
.	NULL

A	NULL
role	NULL
for	NULL
deregulated	NULL
c-myc	NULL
expression	NULL
in	NULL
apoptosis	NULL
of	NULL
Epstein-Barr	NULL
virus-immortalized	NULL
B	NULL
cells	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91:12967-12971	NULL
.	NULL

8	NULL
.	NULL

Edwards	NULL
,	NULL
R.	NULL
H.	NULL
,	NULL
and	NULL
N.	NULL
Raab-Traub	NULL
.	NULL

1994	NULL
.	NULL

Alterations	NULL
of	NULL
the	NULL
p53	NULL
gene	NULL
in	NULL
Epstein-Barr	NULL
virus-associated	NULL
immunodeficiency-related	NULL
lymphomas	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

68:1309-1315	NULL
.	NULL

9	NULL
.	NULL

Effert	NULL
,	NULL
P.	NULL
,	NULL
R.	NULL
McCoy	NULL
,	NULL
M.	NULL
Abdel-Hamid	NULL
,	NULL
K.	NULL
Flynn	NULL
,	NULL
Q.	NULL
Zhang	NULL
,	NULL
P.	NULL
Busson	NULL
,	NULL
T.	NULL
Tursz	NULL
,	NULL
E.	NULL
Lin	NULL
,	NULL
and	NULL
N.	NULL
Raab-Traub	NULL
.	NULL

1992	NULL
.	NULL

Alterations	NULL
of	NULL
the	NULL
p53	NULL
gene	NULL
in	NULL
nasopharyngeal	NULL
carcinoma	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

66:3768-3775	NULL
.	NULL

10	NULL
.	NULL

El-Deiry	NULL
,	NULL
W.	NULL
S.	NULL
,	NULL
T.	NULL
Tokino	NULL
,	NULL
V.	NULL
E.	NULL
Velculescu	NULL
,	NULL
D.	NULL
B	NULL
.	NULL

Levy	NULL
,	NULL
R.	NULL
Parsons	NULL
,	NULL
J.	NULL
M.	NULL
Trent	NULL
,	NULL
D.	NULL
Lin	NULL
,	NULL
W.	NULL
E.	NULL
Mercer	NULL
,	NULL
K.	NULL
W.	NULL
Kinzler	NULL
,	NULL
and	NULL
B.	NULL
Vogelstein	NULL
.	NULL

1993	NULL
.	NULL

WAFI	NULL
,	NULL
a	NULL
potential	NULL
mediator	NULL
of	NULL
p53	NULL
tumor	NULL
suppression	NULL
.	NULL

Cell	NULL
75:817-825	NULL
.	NULL

11	NULL
.	NULL

Fahraeus	NULL
,	NULL
R.	NULL
,	NULL
H.	NULL
Li	NULL
Fu	NULL
,	NULL
I.	NULL
Emnberg	NULL
,	NULL
J.	NULL
Finke	NULL
,	NULL
M.	NULL
Rowe	NULL
,	NULL
G.	NULL
Klein	NULL
,	NULL
K.	NULL
Falk	NULL
,	NULL
E.	NULL
Nilsson	NULL
,	NULL
M.	NULL
Yadav	NULL
,	NULL
P.	NULL
Busson	NULL
,	NULL
T.	NULL
Tursz	NULL
,	NULL
and	NULL
B.	NULL
Kallin	NULL
.	NULL

1988	NULL
.	NULL

Expression	NULL
of	NULL
Epstein-Barr	NULL
virus-encoded	NULL
proteins	NULL
in	NULL
nasopharyngeal	NULL
carcinoma	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
42:329-338	NULL
.	NULL

12	NULL
.	NULL

Farrell	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
G.	NULL
J.	NULL
Allan	NULL
,	NULL
F.	NULL
Shanahan	NULL
,	NULL
K.	NULL
H.	NULL
Vousden	NULL
,	NULL
and	NULL
T.	NULL
Crook	NULL
.	NULL

1991.	NULL
p53	NULL
is	NULL
frequently	NULL
mutated	NULL
in	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
cell	NULL
lines	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

10	NULL
:	NULL
2879-2887	NULL
.	NULL

13	NULL
.	NULL

Fearon	NULL
,	NULL
D.	NULL
T.	NULL
,	NULL
and	NULL
R.	NULL
H.	NULL
Carter	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
CD19/CR2/TAPA-1	NULL
complex	NULL
of	NULL
B	NULL
lymphocytes	NULL
:	NULL
linking	NULL
natural	NULL
to	NULL
acquired	NULL
immunity	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

13:127-149	NULL
.	NULL

14	NULL
.	NULL

Gaidano	NULL
,	NULL
G.	NULL
,	NULL
P.	NULL
Ballerini	NULL
,	NULL
J	NULL
.	NULL

Z.	NULL
Gong	NULL
,	NULL
G.	NULL
Inghirami	NULL
,	NULL
A.	NULL
Neri	NULL
,	NULL
E.	NULL
W.	NULL
Newcomb	NULL
,	NULL
I.	NULL
T.	NULL
Magrath	NULL
,	NULL
D.	NULL
M.	NULL
Knowles	NULL
,	NULL
and	NULL
R.	NULL
Dalla-Favera	NULL
.	NULL

1991.	NULL
p53	NULL
mutations	NULL
in	NULL
human	NULL
lymphoid	NULL
malignancies	NULL
:	NULL
association	NULL
with	NULL
Burkitt	NULL
lymphoma	NULL
and	NULL
chronic	NULL
lymphocytic	NULL
leukemia	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88:5413-5417	NULL
.	NULL

15	NULL
.	NULL

Gordon	NULL
,	NULL
J.	NULL
,	NULL
L.	NULL
Walker	NULL
,	NULL
G.	NULL
Guy	NULL
,	NULL
G.	NULL
Brown	NULL
,	NULL
M.	NULL
Rowe	NULL
,	NULL
and	NULL
A.	NULL
Rickinson	NULL
.	NULL

1986	NULL
.	NULL

Control	NULL
of	NULL
human	NULL
B-lymphocyte	NULL
replication	NULL
.	NULL

II	NULL
.	NULL

Transforming	NULL
Epstein-Barr	NULL
virus	NULL
exploits	NULL
three	NULL
distinct	NULL
viral	NULL
signals	NULL
to	NULL
undermine	NULL
three	NULL
separate	NULL
control	NULL
points	NULL
in	NULL
B-cell	NULL
growth	NULL
.	NULL

Immunology	NULL
58:591-595	NULL
.	NULL

16	NULL
.	NULL

Gorman	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
L.	NULL
F.	NULL
Moffat	NULL
,	NULL
and	NULL
B.	NULL
H.	NULL
Howard	NULL
.	NULL

1982	NULL
.	NULL

Recombinant	NULL
genomes	NULL
which	NULL
express	NULL
chloramphenicol	NULL
acetyltransferase	NULL
in	NULL
mammalian	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

21044-1051.	NULL
voL	NULL
.	NULL

70	NULL
,	NULL
1996	NULL
17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

Green	NULL
,	NULL
S.	NULL
,	NULL
I.	NULL
Issemann	NULL
,	NULL
and	NULL
E.	NULL
Sheer	NULL
.	NULL

1988	NULL
.	NULL

A	NULL
versatile	NULL
in	NULL
vivo	NULL
and	NULL
in	NULL
vitro	NULL
eukaryotic	NULL
expression	NULL
vector	NULL
for	NULL
protein	NULL
engineering	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

16:369	NULL
.	NULL

Hammarskjild	NULL
,	NULL
M.-L.	NULL
,	NULL
and	NULL
M.	NULL
C.	NULL
Simurda	NULL
.	NULL

1992	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
latent	NULL
membrane	NULL
protein	NULL
transactivates	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
long	NULL
terminal	NULL
repeat	NULL
through	NULL
induction	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
activity	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

66:6496-6501	NULL
.	NULL

Hennessy	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1985	NULL
.	NULL

A	NULL
second	NULL
nuclear	NULL
protein	NULL
is	NULL
encoded	NULL
by	NULL
Epstein-Barr	NULL
virus	NULL
in	NULL
latent	NULL
infection	NULL
.	NULL

Science	NULL
227:1238	NULL
.	NULL

Herrero	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
P.	NULL
Mathew	NULL
,	NULL
and	NULL
C.	NULL
V.	NULL
Paya	NULL
.	NULL

1995	NULL
.	NULL

LMP-1	NULL
activates	NULL
NF-	NULL
«	NULL
B	NULL
by	NULL
targeting	NULL
the	NULL
inhibitory	NULL
molecule	NULL
IxBa	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

69:2168-2174	NULL
.	NULL

Ho	NULL
,	NULL
M.	NULL
,	NULL
G.	NULL
Miller	NULL
,	NULL
R.	NULL
W.	NULL
Atchison	NULL
,	NULL
M.	NULL
K.	NULL
Breinig	NULL
,	NULL
J.	NULL
S.	NULL
Dummer	NULL
,	NULL
W.	NULL
Andi-man	NULL
,	NULL
T.	NULL
E.	NULL
Starzl	NULL
,	NULL
R.	NULL
Eastman	NULL
,	NULL
B.	NULL
P.	NULL
Griffith	NULL
,	NULL
R.	NULL
L.	NULL
Hardesty	NULL
,	NULL
H.	NULL
T.	NULL
Bahnson	NULL
,	NULL
T.	NULL
R.	NULL
Hakala	NULL
,	NULL
and	NULL
J.	NULL
T.	NULL
Rosenthal	NULL
.	NULL

1985	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
infections	NULL
and	NULL
DNA	NULL
hybridization	NULL
studies	NULL
in	NULL
posttransplant	NULL
lymphoma	NULL
and	NULL
lymphoproliferative	NULL
lesions	NULL
:	NULL
the	NULL
role	NULL
of	NULL
primary	NULL
infection	NULL
.	NULL

J.	NULL
Infect	NULL
.	NULL

Dis	NULL
.	NULL

152:876-886	NULL
.	NULL

Hollyoake	NULL
,	NULL
M.	NULL
,	NULL
A.	NULL
Stiihler	NULL
,	NULL
P.	NULL
Farrell	NULL
,	NULL
J.	NULL
Gordon	NULL
,	NULL
and	NULL
A.	NULL
Sinclair	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
normal	NULL
cell	NULL
cycle	NULL
activation	NULL
program	NULL
is	NULL
exploited	NULL
during	NULL
the	NULL
infection	NULL
of	NULL
quiescent	NULL
B	NULL
lymphocytes	NULL
by	NULL
Epstein-Barr	NULL
virus	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

55:4784-4787	NULL
.	NULL

Huen	NULL
,	NULL
D.	NULL
S.	NULL
,	NULL
S.	NULL
A.	NULL
Henderson	NULL
,	NULL
D.	NULL
Croom-Carter	NULL
,	NULL
and	NULL
M.	NULL
Rowe	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
latent	NULL
membrane	NULL
protein-1	NULL
(	NULL
LMP1	NULL
)	NULL
mediates	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
cell	NULL
surface	NULL
phenotype	NULL
via	NULL
two	NULL
effector	NULL
regions	NULL
in	NULL
its	NULL
carboxy-terminal	NULL
cytoplasmic	NULL
domain	NULL
.	NULL

Oncogene	NULL
10:549-560	NULL
.	NULL

Hutt-Fletcher	NULL
,	NULL
L.	NULL
M.	NULL
1987	NULL
.	NULL

Synergistic	NULL
activation	NULL
of	NULL
cells	NULL
by	NULL
Epstein-Barr	NULL
virus	NULL
and	NULL
B-cell	NULL
growth	NULL
factor	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

61:774-781	NULL
.	NULL

Karp	NULL
,	NULL
J.	NULL
E.	NULL
,	NULL
and	NULL
S.	NULL
Broder	NULL
.	NULL

1991	NULL
.	NULL

Acquired	NULL
immunodeficiency	NULL
syndrome	NULL
and	NULL
non-Hodgkin	NULL
's	NULL
lymphomas	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

51:4743-4756	NULL
.	NULL

Kempkes	NULL
,	NULL
B.	NULL
,	NULL
D.	NULL
Spitkovsky	NULL
,	NULL
P.	NULL
Jansen-Dirr	NULL
,	NULL
J.	NULL
W.	NULL
Ellwart	NULL
,	NULL
E.	NULL
Kremmer	NULL
,	NULL
H.	NULL
J.	NULL
Delecluse	NULL
,	NULL
C.	NULL
Rottenberger	NULL
,	NULL
G.	NULL
W.	NULL
Bornkamm	NULL
,	NULL
and	NULL
W.	NULL
Hammer-schmidt	NULL
.	NULL

1995	NULL
.	NULL

B-cell	NULL
proliferation	NULL
and	NULL
induction	NULL
of	NULL
early	NULL
G	NULL
;	NULL
,	NULL
-regulating	NULL
proteins	NULL
by	NULL
Epstein-Barr	NULL
virus	NULL
mutants	NULL
conditional	NULL
for	NULL
EBNAZ	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

14:88-96	NULL
.	NULL

Klein	NULL
,	NULL
G.	NULL
1989	NULL
.	NULL

Viral	NULL
latency	NULL
and	NULL
transformation	NULL
:	NULL
the	NULL
strategy	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
.	NULL

Cell	NULL
58:5-8	NULL
.	NULL

Laherty	NULL
,	NULL
C.	NULL
D.	NULL
,	NULL
H.	NULL
M.	NULL
Hu	NULL
,	NULL
A.	NULL
W.	NULL
Opipari	NULL
,	NULL
F.	NULL
Wang	NULL
,	NULL
and	NULL
V.	NULL
M.	NULL
Dixit	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
LMP1	NULL
gene	NULL
product	NULL
induces	NULL
A20	NULL
zinc	NULL
finger	NULL
protein	NULL
expression	NULL
by	NULL
activating	NULL
nuclear	NULL
factor	NULL
xB	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

267:24157-24160	NULL
.	NULL

Lane	NULL
,	NULL
D.	NULL
P.	NULL
1992.	NULL
p53	NULL
,	NULL
guardian	NULL
of	NULL
the	NULL
genome	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
358:15-16	NULL
.	NULL

Lane	NULL
,	NULL
D.	NULL
P.	NULL
,	NULL
and	NULL
L.	NULL
V.	NULL
Crawford	NULL
.	NULL

1979	NULL
.	NULL

T	NULL
antigen	NULL
is	NULL
bound	NULL
to	NULL
a	NULL
host	NULL
protein	NULL
in	NULL
SV40-transformed	NULL
cells	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
278:261-263	NULL
.	NULL

Linzer	NULL
,	NULL
D.	NULL
I.	NULL
H.	NULL
,	NULL
and	NULL
A.	NULL
J.	NULL
Levine	NULL
.	NULL

1979	NULL
.	NULL

Characterization	NULL
of	NULL
a	NULL
54,000	NULL
MW	NULL
cellular	NULL
SV40	NULL
tumor	NULL
antigen	NULL
present	NULL
in	NULL
SV40-transformed	NULL
cells	NULL
and	NULL
uninfected	NULL
embryonal	NULL
carcinoma	NULL
cells	NULL
.	NULL

Cell	NULL
17:43-52	NULL
.	NULL

Luxembourg	NULL
,	NULL
A.	NULL
T.	NULL
,	NULL
and	NULL
N.	NULL
R.	NULL
Cooper	NULL
.	NULL

1994	NULL
.	NULL

T	NULL
cell	NULL
dependent	NULL
B	NULL
cell	NULL
activating	NULL
properties	NULL
of	NULL
antibody-coated	NULL
small	NULL
latex	NULL
beads	NULL
:	NULL
a	NULL
new	NULL
model	NULL
for	NULL
B	NULL
cell	NULL
activation	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

153:604-614	NULL
.	NULL

Mann	NULL
,	NULL
K.	NULL
P.	NULL
,	NULL
D.	NULL
Staunton	NULL
,	NULL
and	NULL
D.	NULL
A.	NULL
Thorley-Lawson	NULL
.	NULL

1985	NULL
.	NULL

Epstcin-Barr	NULL
virus-encoded	NULL
protein	NULL
found	NULL
in	NULL
plasma	NULL
membranes	NULL
of	NULL
transformed	NULL
cells	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

55:710-720	NULL
.	NULL

Mitchell	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
B.	NULL
Sugden	NULL
.	NULL

1995	NULL
.	NULL

Stimulation	NULL
of	NULL
NF-	NULL
«	NULL
B-mediated	NULL
transcription	NULL
by	NULL
mutant	NULL
derivatives	NULL
of	NULL
the	NULL
latent	NULL
membrane	NULL
protein	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

69:2968-2976	NULL
.	NULL

Mulligan	NULL
,	NULL
R.	NULL
C.	NULL
,	NULL
and	NULL
P.	NULL
Berg	NULL
.	NULL

1981	NULL
.	NULL

Selection	NULL
for	NULL
animal	NULL
cells	NULL
that	NULL
express	NULL
the	NULL
Escherichia	NULL
coli	NULL
gene	NULL
coding	NULL
for	NULL
xanthine-guanine	NULL
phosphoribosyltrans-ferase	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
78:2072-2076	NULL
.	NULL

Nakamura	NULL
,	NULL
H.	NULL
,	NULL
J.	NULL
W.	NULL
Said	NULL
,	NULL
C.	NULL
W.	NULL
Miller	NULL
,	NULL
and	NULL
H.	NULL
P.	NULL
Koeffler	NULL
.	NULL

1993	NULL
.	NULL

Mutation	NULL
and	NULL
protein	NULL
expression	NULL
of	NULL
p53	NULL
in	NULL
acquired	NULL
immunodeficiency	NULL
syndrome-related	NULL
lymphomas	NULL
.	NULL

Blood	NULL
82:920-926	NULL
.	NULL

Nemerow	NULL
,	NULL
G.	NULL
R.	NULL
,	NULL
and	NULL
N.	NULL
R.	NULL
Cooper	NULL
.	NULL

1981	NULL
.	NULL

Isolation	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
and	NULL
studies	NULL
of	NULL
its	NULL
neutralization	NULL
by	NULL
human	NULL
IgG	NULL
and	NULL
complement	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

127:272-278	NULL
.	NULL

Nemerow	NULL
,	NULL
G.	NULL
R.	NULL
,	NULL
A.	NULL
T.	NULL
Luxembourg	NULL
,	NULL
and	NULL
N.	NULL
R.	NULL
Cooper	NULL
.	NULL

1994	NULL
.	NULL

CD21/CR2	NULL
:	NULL
its	NULL
role	NULL
in	NULL
EBV	NULL
infection	NULL
and	NULL
immune	NULL
function	NULL
.	NULL

Epstein-Barr	NULL
Rep.	NULL
1:59-64	NULL
.	NULL

Oren	NULL
,	NULL
M.	NULL
1992.	NULL
p53	NULL
:	NULL
the	NULL
ultimate	NULL
tumor	NULL
suppressor	NULL
gene	NULL
?	NULL

FASEB	NULL
J	NULL
.	NULL

6:3169-3176	NULL
.	NULL

Pallesen	NULL
,	NULL
G.	NULL
,	NULL
S.	NULL
J.	NULL
Hamilton-Dutoit	NULL
,	NULL
M.	NULL
Rowe	NULL
,	NULL
and	NULL
L.	NULL
S.	NULL
Young	NULL
.	NULL

1991	NULL
.	NULL

Expression	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
latent	NULL
gene	NULL
products	NULL
in	NULL
tumour	NULL
cells	NULL
of	NULL
Hodgkin	NULL
's	NULL
disease	NULL
.	NULL

Lancet	NULL
337:320-322	NULL
.	NULL

Palmero	NULL
,	NULL
L.	NULL
,	NULL
A	NULL
.	NULL

Holder	NULL
,	NULL
A.	NULL
J.	NULL
Sinclair	NULL
,	NULL
C.	NULL
Dickson	NULL
,	NULL
and	NULL
G.	NULL
Peters	NULL
.	NULL

1993	NULL
.	NULL

Cyclins	NULL
D1	NULL
and	NULL
D2	NULL
are	NULL
differentially	NULL
expressed	NULL
in	NULL
human	NULL
B-lymphoid	NULL
cell	NULL
lines	NULL
.	NULL

Oncogene	NULL
8:1049-1054	NULL
.	NULL

Rooney	NULL
,	NULL
C.	NULL
,	NULL
J.	NULL
G.	NULL
Howe	NULL
,	NULL
S.	NULL
H.	NULL
Speck	NULL
,	NULL
and	NULL
G.	NULL
Miller	NULL
.	NULL

1989	NULL
.	NULL

Influences	NULL
of	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
and	NULL
primary	NULL
B	NULL
cells	NULL
on	NULL
latent	NULL
gene	NULL
expression	NULL
by	NULL
the	NULL
nonimmortalizing	NULL
P3J-HR-1	NULL
strain	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:1531-1539	NULL
.	NULL

Rosen	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
J.	NULL
G.	NULL
Sodroski	NULL
,	NULL
and	NULL
W.	NULL
A.	NULL
Haseltine	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
location	NULL
of	NULL
cis-acting	NULL
regulatory	NULL
sequences	NULL
in	NULL
the	NULL
human	NULL
T	NULL
cell	NULL
lymphotropic	NULL
virus	NULL
type	NULL
44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

59	NULL
.	NULL

60	NULL
.	NULL

61	NULL
.	NULL

62	NULL
.	NULL

63	NULL
.	NULL

64	NULL
.	NULL

65	NULL
.	NULL

66	NULL
.	NULL

NOTES	NULL
4853	NULL
II	NULL
(	NULL
HTLV-III/LAV	NULL
)	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

Cell	NULL
41:813-823	NULL
.	NULL

Rowe	NULL
,	NULL
M.	NULL
,	NULL
M.	NULL
Peng-Pilon	NULL
,	NULL
D.	NULL
S.	NULL
Huen	NULL
,	NULL
R.	NULL
Hardy	NULL
,	NULL
D.	NULL
Croom-Carter	NULL
,	NULL
E.	NULL
Lundgren	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Rickinson	NULL
.	NULL

1994	NULL
.	NULL

Upregulation	NULL
of	NULL
be/-2	NULL
by	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
latent	NULL
membrane	NULL
protein	NULL
LMP1	NULL
:	NULL
a	NULL
B-cell-specific	NULL
response	NULL
that	NULL
is	NULL
delayed	NULL
relative	NULL
to	NULL
NF-kB	NULL
activation	NULL
and	NULL
to	NULL
induction	NULL
of	NULL
cell	NULL
surface	NULL
mark-ers	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

68:5602-5612	NULL
.	NULL

Said	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
R.	NULL
Barrera	NULL
,	NULL
I.	NULL
P.	NULL
Shinaku	NULL
,	NULL
H.	NULL
Nakamura	NULL
,	NULL
and	NULL
H.	NULL
P.	NULL
Koeffler	NULL
.	NULL

1992	NULL
.	NULL

Immunohistochemical	NULL
analysis	NULL
of	NULL
p53	NULL
expression	NULL
in	NULL
malignant	NULL
lymphomas	NULL
.	NULL

Am	NULL
.	NULL

J.	NULL
Pathol	NULL
.	NULL

141:1343-1348	NULL
.	NULL

Sarnow	NULL
,	NULL
P.	NULL
,	NULL
Y.	NULL
S.	NULL
Ho	NULL
,	NULL
J.	NULL
Williams	NULL
,	NULL
and	NULL
A.	NULL
J.	NULL
Levine	NULL
.	NULL

1982	NULL
.	NULL

Adenovirus	NULL
E1b-58kd	NULL
tumor	NULL
antigen	NULL
and	NULL
SV40	NULL
large	NULL
tumor	NULL
antigen	NULL
are	NULL
physically	NULL
associated	NULL
with	NULL
the	NULL
same	NULL
54kd	NULL
cellular	NULL
protein	NULL
in	NULL
transformed	NULL
cells	NULL
.	NULL

Cell	NULL
28:387-394	NULL
.	NULL

Scala	NULL
,	NULL
G.	NULL
,	NULL
I.	NULL
Quinto	NULL
,	NULL
M.	NULL
R.	NULL
Ruocco	NULL
,	NULL
M.	NULL
Mallardo	NULL
,	NULL
C.	NULL
Ambrosino	NULL
,	NULL
B.	NULL
Squitieri	NULL
,	NULL
P.	NULL
Tassone	NULL
,	NULL
and	NULL
S.	NULL
Venuta	NULL
.	NULL

1993	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
nuclear	NULL
antigen	NULL
2	NULL
transactivates	NULL
the	NULL
long	NULL
terminal	NULL
repeat	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

67:2853-2861	NULL
.	NULL

Scheffner	NULL
,	NULL
M.	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
Werness	NULL
,	NULL
J.	NULL
M.	NULL
Huibregtse	NULL
,	NULL
A.	NULL
J.	NULL
Levine	NULL
,	NULL
and	NULL
P.	NULL
M.	NULL
Howley	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
E6	NULL
oncoprotein	NULL
encoded	NULL
by	NULL
human	NULL
papillomavirus	NULL
types	NULL
16	NULL
and	NULL
18	NULL
promotes	NULL
the	NULL
degradation	NULL
of	NULL
p53	NULL
.	NULL

Cell	NULL
63:1129-1136	NULL
.	NULL

Schreiber	NULL
,	NULL
E.	NULL
,	NULL
P.	NULL
Matthias	NULL
,	NULL
M.	NULL
M.	NULL
Miiller	NULL
,	NULL
and	NULL
W.	NULL
Schaffner	NULL
.	NULL

1989	NULL
.	NULL

Rapid	NULL
detection	NULL
of	NULL
octamer	NULL
binding	NULL
proteins	NULL
with	NULL
``	NULL
mini	NULL
extracts	NULL
``	NULL
,	NULL
prepared	NULL
from	NULL
a	NULL
small	NULL
number	NULL
of	NULL
cells	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

17:6419	NULL
.	NULL

Sinclair	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
I	NULL
Palmero	NULL
,	NULL
G.	NULL
Peters	NULL
,	NULL
and	NULL
P.	NULL
J.	NULL
Farrell	NULL
.	NULL

1994	NULL
.	NULL

EBNA-2	NULL
and	NULL
EBNA-LP	NULL
cooperate	NULL
to	NULL
cause	NULL
G	NULL
,	NULL
to	NULL
G	NULL
;	NULL
transition	NULL
during	NULL
immortalization	NULL
of	NULL
resting	NULL
human	NULL
B	NULL
lymphocytes	NULL
by	NULL
Epstein-Barr	NULL
virus	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

13:3321-3328	NULL
.	NULL

Su	NULL
,	NULL
L.-J	NULL
.	NULL

,	NULL
H.-C.	NULL
Hsieh	NULL
,	NULL
K.-H.	NULL
Lin	NULL
,	NULL
W.-C.	NULL
Uen	NULL
,	NULL
C.-L.	NULL
Kao	NULL
,	NULL
C.-J	NULL
.	NULL

Chen	NULL
,	NULL
A-L.	NULL
Cheng	NULL
,	NULL
M.	NULL
E.	NULL
Kadin	NULL
,	NULL
and	NULL
J.-Y	NULL
.	NULL

Chen	NULL
.	NULL

1991	NULL
.	NULL

Aggressive	NULL
peripheral	NULL
T-cell	NULL
lymphomas	NULL
containing	NULL
Epstein-Barr	NULL
viral	NULL
DNA	NULL
:	NULL
a	NULL
clinicopathologic	NULL
and	NULL
molecular	NULL
analysis	NULL
.	NULL

Blood	NULL
77:799-808	NULL
.	NULL

Sun	NULL
,	NULL
Y.	NULL
,	NULL
G.	NULL
Hegamyer	NULL
,	NULL
Y.-J	NULL
.	NULL

Cheng	NULL
,	NULL
and	NULL
I.-H.	NULL
Chen	NULL
.	NULL

1992	NULL
.	NULL

An	NULL
infrequent	NULL
point	NULL
mutation	NULL
of	NULL
the	NULL
p53	NULL
gene	NULL
in	NULL
human	NULL
nasopharyngeal	NULL
carcinoma	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89:6516-6520	NULL
.	NULL

Szekely	NULL
,	NULL
L.	NULL
,	NULL
K.	NULL
Pokrovskaja	NULL
,	NULL
W.-Q	NULL
.	NULL

Jiang	NULL
,	NULL
G.	NULL
Selivanova	NULL
,	NULL
M.	NULL
Lowbeer	NULL
,	NULL
N.	NULL
Ringertz	NULL
,	NULL
K.	NULL
G.	NULL
Wiman	NULL
,	NULL
and	NULL
G.	NULL
Klein	NULL
.	NULL

1995	NULL
.	NULL

Resting	NULL
B-cells	NULL
,	NULL
EBV-infected	NULL
B-blasts	NULL
and	NULL
established	NULL
lymphoblastoid	NULL
cell	NULL
lines	NULL
differ	NULL
in	NULL
their	NULL
Rb	NULL
,	NULL
p53	NULL
and	NULL
EBNA-5	NULL
expression	NULL
patterns	NULL
.	NULL

Oncogene	NULL
10:1869-1874	NULL
.	NULL

Szekely	NULL
,	NULL
L.	NULL
,	NULL
G.	NULL
Selivanova	NULL
,	NULL
K.	NULL
P.	NULL
Magnusson	NULL
,	NULL
G.	NULL
Klein	NULL
,	NULL
and	NULL
K.	NULL
G.	NULL
Wiman	NULL
.	NULL

1993	NULL
.	NULL

EBNA-5	NULL
,	NULL
an	NULL
Epstein-Barr	NULL
virus-encoded	NULL
nuclear	NULL
antigen	NULL
,	NULL
binds	NULL
to	NULL
the	NULL
retinoblastoma	NULL
and	NULL
p53	NULL
proteins	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90:5455-5499	NULL
.	NULL

Tanner	NULL
,	NULL
J.	NULL
,	NULL
Y.	NULL
Whang	NULL
,	NULL
J	NULL
.	NULL

Sample	NULL
,	NULL
A.	NULL
Sears	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1988	NULL
.	NULL

Soluble	NULL
gp350/220	NULL
and	NULL
deletion	NULL
mutant	NULL
glycoproteins	NULL
block	NULL
Epstein-Barr	NULL
virus	NULL
ad-sorption	NULL
to	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

62:4452-4464	NULL
.	NULL

Thomas	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
M.	NULL
J.	NULL
Allday	NULL
,	NULL
and	NULL
D.	NULL
H.	NULL
Crawford	NULL
.	NULL

1991	NULL
.	NULL

Epstein-Barr	NULL
virus-associated	NULL
lymphoproliferative	NULL
disorders	NULL
in	NULL
immunocompromised	NULL
individu-als	NULL
.	NULL

Adv	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

57:329-380	NULL
.	NULL

Triimper	NULL
,	NULL
L.	NULL
H.	NULL
,	NULL
G.	NULL
Brady	NULL
,	NULL
A.	NULL
Bagg	NULL
,	NULL
D.	NULL
Gray	NULL
,	NULL
S.	NULL
L.	NULL
Loke	NULL
,	NULL
H.	NULL
Griesser	NULL
,	NULL
R.	NULL
Wagman	NULL
,	NULL
R.	NULL
Braziel	NULL
,	NULL
R.	NULL
D.	NULL
Gascoyne	NULL
,	NULL
S.	NULL
Vicini	NULL
,	NULL
N.	NULL
N.	NULL
Iscove	NULL
,	NULL
J.	NULL
Cossman	NULL
,	NULL
and	NULL
T.	NULL
W.	NULL
Mak	NULL
.	NULL

1993	NULL
.	NULL

Single-cell	NULL
analysis	NULL
of	NULL
Hodgkin	NULL
and	NULL
Reed-Sternberg	NULL
cells	NULL
:	NULL
molecular	NULL
heterogeneity	NULL
of	NULL
gene	NULL
expression	NULL
and	NULL
p53	NULL
mutations	NULL
.	NULL

Blood	NULL
81:3097-3115	NULL
.	NULL

Wang	NULL
,	NULL
D.	NULL
,	NULL
D.	NULL
Liebowitz	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1985	NULL
.	NULL

An	NULL
Epstein-Barr	NULL
virus	NULL
membrane	NULL
protein	NULL
expressed	NULL
in	NULL
immortalized	NULL
lymphocytes	NULL
transforms	NULL
established	NULL
rodent	NULL
cells	NULL
.	NULL

Cell	NULL
43:831-840	NULL
.	NULL

Wang	NULL
,	NULL
F.	NULL
,	NULL
S.-F.	NULL
Tsang	NULL
,	NULL
M.	NULL
G.	NULL
Kurilla	NULL
,	NULL
J.	NULL
L	NULL
Cohen	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1990	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
nuclear	NULL
antigen	NULL
2	NULL
transactivates	NULL
latent	NULL
membrane	NULL
protein	NULL
LMP1	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:3407-3416	NULL
.	NULL

Werness	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
,	NULL
A.	NULL
J.	NULL
Levine	NULL
,	NULL
and	NULL
P.	NULL
M.	NULL
Howley	NULL
.	NULL

1990	NULL
.	NULL

Association	NULL
of	NULL
human	NULL
papillomavirus	NULL
types	NULL
16	NULL
and	NULL
18	NULL
E6	NULL
proteins	NULL
with	NULL
p53	NULL
.	NULL

Science	NULL
248:76-79	NULL
.	NULL

Wiman	NULL
,	NULL
K.	NULL
G.	NULL
,	NULL
K.	NULL
P.	NULL
Magnusson	NULL
,	NULL
T.	NULL
Ramqvist	NULL
,	NULL
and	NULL
G.	NULL
Klein	NULL
.	NULL

1991	NULL
.	NULL

Mutant	NULL
p53	NULL
detected	NULL
in	NULL
a	NULL
majority	NULL
of	NULL
Burkitt	NULL
lymphoma	NULL
cell	NULL
lines	NULL
by	NULL
monoclonal	NULL
antibody	NULL
PAb240	NULL
.	NULL

Oncogene	NULL
6:1633-1639	NULL
.	NULL

Wu	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
G.	NULL
Lozano	NULL
.	NULL

1994	NULL
.	NULL

NF-kB	NULL
activation	NULL
of	NULL
p53	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269:20067-20074	NULL
.	NULL

Wu	NULL
,	NULL
X.	NULL
,	NULL
H.	NULL
Bayle	NULL
,	NULL
D.	NULL
Olson	NULL
,	NULL
and	NULL
A.	NULL
J.	NULL
Levine	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
p53-mdm-2	NULL
auto-regulatory	NULL
feedback	NULL
loop	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

7:1126-1132	NULL
.	NULL

Young	NULL
,	NULL
L.	NULL
,	NULL
C.	NULL
Alfieri	NULL
,	NULL
K.	NULL
Hennessy	NULL
,	NULL
H.	NULL
Evans	NULL
,	NULL
C.	NULL
O'Hara	NULL
,	NULL
K.	NULL
C.	NULL
Anderson	NULL
,	NULL
J.	NULL
Ritz	NULL
,	NULL
R.	NULL
S.	NULL
Shapiro	NULL
,	NULL
A.	NULL
Rickinson	NULL
,	NULL
E.	NULL
Kieff	NULL
,	NULL
and	NULL
J.	NULL
I.	NULL
Cohen	NULL
.	NULL

1989	NULL
.	NULL

Expression	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
transformation-associated	NULL
genes	NULL
in	NULL
tissues	NULL
of	NULL
patients	NULL
with	NULL
EBV	NULL
lymphoproliferative	NULL
disease	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

321:1080-1085	NULL
.	NULL

Zantema	NULL
,	NULL
A.	NULL
,	NULL
P.	NULL
I.	NULL
Schrier	NULL
,	NULL
A.	NULL
Davis-Olivier	NULL
,	NULL
T.	NULL
van	NULL
Laar	NULL
,	NULL
R.	NULL
T.	NULL
M.	NULL
J.	NULL
Vaessen	NULL
,	NULL
and	NULL
A.	NULL
J.	NULL
van	NULL
der	NULL
Eb	NULL
.	NULL

1985	NULL
.	NULL

Adenovirus	NULL
serotype	NULL
determines	NULL
association	NULL
and	NULL
localization	NULL
of	NULL
the	NULL
large	NULL
E1B	NULL
tumor	NULL
antigen	NULL
with	NULL
cellular	NULL
tumor	NULL
antigen	NULL
p53	NULL
in	NULL
transformed	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

5:3084-3091	NULL
.	NULL

Zhang	NULL
,	NULL
Q.	NULL
,	NULL
D.	NULL
Gutsch	NULL
,	NULL
and	NULL
S.	NULL
Kenney	NULL
.	NULL

1994	NULL
.	NULL

Functional	NULL
and	NULL
physical	NULL
interaction	NULL
between	NULL
p53	NULL
and	NULL
BZLF1	NULL
:	NULL
implications	NULL
for	NULL
Epstein-Barr	NULL
virus	NULL
latency	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:1929-1938	NULL
.	NULL

